

EVIDENCE-BASED RESOURCE GUIDE SERIES

Preventing the Use of Marijuana: Focus on Women and Pregnancy



SAMHSA
Substance Abuse and Mental Health
Services Administration

Acknowledgments

This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) under contract number HHSS28320170006511/HHSS28342001T with SAMHSA. Thomas Clarke served as contracting officer representative.

Disclaimer

The views, opinions, and content of this publication are those of the authors and do not necessarily reflect the views, opinions, or policies of SAMHSA. Nothing in this document constitutes a direct or indirect endorsement by SAMHSA of any non-federal entity's products, services, or policies, and any reference to non-federal entity's products, services, or policies should not be construed as such.

Public Domain Notice

All material appearing in this publication is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA.

Electronic Access

This publication may be downloaded from <http://store.samhsa.gov>

Recommended Citation

Substance Abuse and Mental Health Services Administration (SAMHSA). Preventing the Use of Marijuana: Focus on Women and Pregnancy. SAMHSA Publication No. PEP19-PL-Guide-2 Rockville, MD: National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration, 2019.

Originating Office

National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, SAMHSA Publication No. PEP19-PL-Guide-2.

Nondiscrimination Notice

SAMHSA complies with applicable federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

SAMHSA cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, ni edad.



MESSAGE FROM THE ASSISTANT SECRETARY FOR MENTAL HEALTH AND SUBSTANCE USE, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

As the first U.S. Department of Health and Human Services Assistant Secretary for Mental Health and Substance Use at the Substance Abuse and Mental Health Services Administration (SAMHSA), I am pleased to present this new resource: *Preventing the Use of Marijuana: Focus on Women and Pregnancy*. In response to the charge of the 21st Century Cures Act to disseminate information on evidence-based practices and service delivery models, the National Mental Health and Substance Use Policy Lab has developed the Evidence-Based Resource Guide Series focused on the prevention and treatment of substance use disorders and mental illnesses. With this guide, SAMHSA's goal is to inform women and their health care providers of the potential effects of marijuana use, especially during pregnancy and the postpartum period.

According to the National Survey on Drug Use and Health (NSDUH), an estimated 53.2 million people used illicit drugs in the past year among those who are 12 and older. The most commonly used illicit drug in the past year was marijuana, which was used by 43.5 million people. In 2017, NSDUH showed that pregnant women were using substances in greater number, including significant increases in daily or nearly daily marijuana use. In the 2018 NSDUH data, the news is more encouraging, as there was a significant decline in illicit drug use, including marijuana, by pregnant women. However, NSDUH showed daily use of marijuana by women who are not pregnant continued to increase.¹

Preventing the Use of Marijuana: Focus on Women and Pregnancy addresses the established health risks of marijuana use to pregnant women and their children, as well as the expanding evidence base on other potential harms of use during pregnancy. I encourage you to use this guide to be informed of the adverse health consequences and potential effects of marijuana use, and to promote healthy decision-making among pregnant and postpartum women.

Elinore F. McCance-Katz, M.D., Ph.D.

Assistant Secretary for Mental Health and Substance Use
U.S. Department of Health and Human Services

Reference List

1. Substance Abuse and Mental Health Services Administration (SAMHSA). (2019). *Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health*. Rockville, MD: Center for Behavioral Health Statistics and Quality, SAMHSA.

Evidence-Based Resource Guide Series Overview

The Substance Abuse and Mental Health Services Administration (SAMHSA), and specifically, the National Mental Health and Substance Use Policy Laboratory, is pleased to fulfill the charge of the 21st Century Cures Act and disseminate information on evidence-based practices and service delivery models to prevent substance misuse and help individuals with substance use disorders (SUD), serious mental illnesses (SMI), and serious emotional disturbances (SED) get the treatment and support that they need.

Individuals in treatment and recovery vary in many ways. They face different mental and substance use disorders, may have co-occurring disorders, live in diverse parts of the country, and face a variety of socio-economic factors that help or hinder recovery. All these factors bring complexities to evaluating the effectiveness of services, treatments, and supports for the prevention and treatment of mental and substance use disorders.

Despite variations, *substantial evidence is available* to understand the types of services, treatments, and supports that prevent and reduce substance use, lessen mental illness symptoms, and improve individuals' quality of life. Communities are eager to take advantage of what has been learned to help individuals in need.

The Evidence-Based Resource Guide Series is a comprehensive and modular set of resources intended to support healthcare providers, health care system administrators, and community members to meet the needs of individuals at risk for, experiencing, or recovering from substance use disorder and mental illness.

With this Resource Guide, SAMHSA's goal is to inform women of the potential effects of marijuana use, especially during pregnancy and during the postpartum period, and to promote healthy decision-making among this population. This guide examines the scientific literature on the risk factors for and adverse health consequences of marijuana use during pregnancy. It examines emerging and best practices to prevent or reduce such use. The guide also identifies key components of peer-reviewed models and discusses the challenges and strategies involved in implementing prevention programs.

Each guide in this series was developed through input from a technical expert panel representing the federal, state, and non-governmental sectors. Panels included accomplished scientists, service providers, community administrators, and federal and state policy makers.

The expert panel members for this guide provided input based on their knowledge of health care systems, implementation of evidence-based practices, provision of services, and policies that foster change.

One Piece of a Multipronged Approach

Research shows that implementing evidence-based practices requires a comprehensive, multipronged approach. This guide is one piece of an overall approach to implement and sustain change. Users are encouraged to review the [SAMHSA website](#) for additional tools and technical assistance opportunities.

Content of the Guide

Each guide contains a foreword and five chapters. The chapters are modular, and do not need to be read in chronological order.

FW Evidence-Based Resource Guide Series Overview

Introduction to the series.

1 Issue Brief

Overview of the issue of marijuana use among pregnant and postpartum women.

2 What Research Tells Us

Review of evidence-based prevention practices, policies, and programs for addressing marijuana use among pregnant and postpartum women.

3 Examples of Effective Prevention Programs

Highlights from a sample of programs that use evidence-based practices to prevent substance use by pregnant and postpartum women.

4 Implementing Evidence-Based Marijuana Use Prevention Practices for Pregnant and Postpartum Women

Practical information to consider when implementing a marijuana use prevention program for pregnant and postpartum women.

5 Marijuana Use Prevention Resources for Implementation, Quality Improvement, and Evaluation of Programs

Resources for implementing evidence-based prevention practices and programs, maintaining high-quality prevention efforts, and monitoring outcomes.

Focus of the Guide

Currently, there is no evidence on individual programs for the prevention of marijuana use among pregnant and postpartum women, and there is a need to address this research gap. This guide draws from evidence-based practices and strategies for the prevention of substance use issues (e.g., alcohol, tobacco). Elements from these evidence-based approaches may apply to marijuana use prevention, and may help clinicians and community-based providers address the risks associated with the use of marijuana by pregnant and postpartum women.

There is a misperception of safety associated with marijuana use. Some women report strong beliefs about using “natural remedies” such as marijuana to address pregnancy-related symptoms such as nausea and anxiety.

Before clinicians and community-based prevention providers can communicate about the adverse health consequences that may be associated with marijuana use before, during, and after pregnancy, it is helpful to understand the existing evidence around the effects of marijuana exposure on fetal and infant outcomes.

ISSUE BRIEF

Preventing the Use of Marijuana: Focus on Women and Pregnancy

National estimates show that between 3 and 7 percent of pregnant women report using marijuana while pregnant.^{1,2} In 2018, there was a significant decline in illicit drug use by pregnant women. The decrease in marijuana use among pregnant women between 2017 and 2018 (7.1 to 4.7 percent) contributed to this overall decline.² A study of self-reported and biochemically tested marijuana use among pregnant women in California found that marijuana use during pregnancy was more common among younger women, with rates as high as 22 percent of pregnant adolescents and 19 percent of pregnant young adults (ages 19–24) screening positive for marijuana use.³

To assist clinicians and others in raising awareness of the known and potential harms of marijuana use during pregnancy, this guide focuses on the growing body of evidence related to maternal marijuana use. The evidence from population-based data on potential harms to newborns is mixed. Some studies rely on self-reported data, which can underestimate the proportion of women who are using marijuana and skew study findings. Other factors, such as concurrent substance use, stress, socioeconomic status, and others, can influence the baby's health.

Despite these limitations, evidence is mounting to show that babies born to mothers who report marijuana use are more likely to be preterm and underweight.^{4,5,6,7}

Further, there is concern that marijuana is transferred through breast milk to the child.^{8,9} The primary psychoactive ingredient in marijuana, delta-9-tetrahydrocannabinol (THC), has been found in breast milk for up to six days after maternal marijuana use.⁹ Marijuana may cause problems with a newborn's brain development and may result in hyperactivity, poor function, and other consequences.¹⁰ While further research is needed to establish whether there are adverse effects on infant development, the American Academy of Pediatrics states that breastfeeding is contraindicated in women using illicit drugs.¹¹

Evidence suggests that women's concerns about how substances will affect the developing fetus can motivate them to reduce or abstain from substances (e.g., alcohol, tobacco, and illicit drugs) during pregnancy.^{12,13} However, relapse tends to rise dramatically from 6 to 12 months following birth among women who abstain from marijuana use during pregnancy.¹³ The postpartum period, from birth through approximately 12 months after birth, corresponds to a critical developmental period for infants.

This chapter provides an overview of marijuana use among pregnant and postpartum women, as well as the adverse health consequences for mothers and their babies that may be associated with marijuana use both during and after pregnancy.

Key Definitions

For this guide, the word “marijuana” is most often used to align with the general public’s understanding of the term.⁵

Marijuana: Refers to the cannabis plant or derivative products that contain more than 0.3 percent of the chemical compound delta-9-tetrahydrocannabinol (THC), the main psychoactive component of marijuana responsible for the plant’s intoxicating effects.⁴

Cannabis Use Disorder: A persisting pattern of cannabis use that results in clinically significant functional impairment in two or more domains (e.g., school, work, social and recreational activities, interpersonal relationships), within a 12-month period. Cannabis use disorder can be classified as mild, moderate, or severe.¹⁵

Cannabinoids: A group of chemical compounds found in cannabis. Among the more than 100 types of cannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).¹⁴

Cannabidiol (CBD): Cannabidiol is a component of the cannabis plant that does not produce a high. Research is exploring its therapeutic potential for pain, anxiety, inflammation, and substance use disorder. An FDA-approved medication, Epidiolex, which is used to treat certain seizure disorders in children, is made from plant-derived cannabidiol. CBD can be extracted from hemp plants (containing less than 0.3% THC) and is currently being marketed in many forms for mostly unproven indications.¹⁶

Delta-9-Tetrahydrocannabinol (THC): The main psychoactive chemical in marijuana that is responsible for most of the intoxicating effects that people seek.¹⁷ Marijuana potency is determined by levels of THC, which vary widely among marijuana products.

Hemp: A strain of the *Cannabis sativa* plant that contains less than 0.3 percent THC. Many CBD products are derived from hemp, though they are not yet regulated by the FDA and may be of questionable quality and consistency.¹⁷

Substance Misuse: The initial use of substances before an individual develops a substance use disorder. This includes excessive use of a legal substance (e.g., alcohol), use of a prescription drug in a manner or dose other than as prescribed (e.g., opioids or stimulants), or any use of an illicit drug (e.g., heroin, cocaine, alcohol for minors).^{16,17,19}

Medical Marijuana Use: The use of the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness as recommended by an authorized practitioner in a state with a medical marijuana law. The FDA has not recognized or approved the marijuana plant as medicine. Continued research may lead to the development of more medications.¹⁶

Recreational Marijuana: Marijuana used for non-medical purposes in jurisdictions that have legalized the purchase, possession, or consumption of cannabis for recreational use by an adult resident (21 or older).

Child-Bearing Age: Ranges of ages during which a woman may become pregnant. Child-bearing age is typically defined as 15–44 or 15–49 years of age, although it is understood that girls younger than 15 may become pregnant.^{20,21}

Prevention Practice: A type of approach, technique, or strategy focused on prevention; for example, skill building with young adults or public service announcements regarding the harmful effects of marijuana use on the brain.²²

Prevention Program: A set of predetermined, structured, and coordinated activities focused on prevention. A program can incorporate different practices. Guidance for implementing a specific prevention practice can be developed and distributed as a prevention program.²²


Prevention Policies: Laws, regulations, procedures, administrative actions, incentives, or voluntary practices of governments and other institutions to promote improvements in health through evidence-based health interventions.²³

Women Who Use Marijuana During Pregnancy

In 2018, **5.4 percent** of women reported using illicit drugs during pregnancy.² The drug most commonly used by pregnant women was marijuana.²

Notably, **34–60 percent** of women who use marijuana continue use during pregnancy, with many believing that it is relatively safe to use during pregnancy and less expensive than tobacco.²⁴

Socioeconomic conditions and other risk factors such as those listed below may contribute to the same pregnancy outcomes otherwise attributed to marijuana. As a result, it is difficult to assess how much of an effect is specifically due to marijuana exposure. Compared to women who do not use marijuana during pregnancy, women who use marijuana during pregnancy:



Risk Factors for Marijuana Use

Research suggests that, in addition to personal factors, the social contexts in which people grow up, live, work, and play have a major influence on marijuana use and on the development of cannabis use disorder.²⁴

While research on risk factors specific to marijuana use during pregnancy and the postpartum period is limited, evidence from broader young adult populations may be relevant for understanding and preventing substance misuse among pregnant and postpartum women.

Factors that can contribute to marijuana use in young adults include use by peers, family members, accessibility, and beliefs about whether or not marijuana is harmful. Additional factors contributing to cannabis use disorder in young adults also may be related to genetics, early trauma, or mental illness. Other influences driving use can include fluctuations in family structure, maternal substance use, poor academic performance, sexual or physical trauma, early initiation of smoking and alcohol consumption, and aggression and delinquency. Furthermore, risk factors such as early initiation, beliefs about risks and benefits, and access to or availability of marijuana are particularly relevant to pregnant and postpartum women.^{25,28, 32,33}

Early Initiation of Marijuana Use

Early onset of marijuana use is associated with a higher risk of developing cannabis use disorder.³⁴

With regard to the development of cannabis use disorder, several different studies have found varying rates of cannabis use disorder among lifetime users, ranging from 9 percent to nearly 20 percent.³⁵

Beliefs About Risks and Benefits of Marijuana

Recent research points to changing perceptions about the harms of marijuana use. In 2018, one in four 12th graders reported that regular marijuana use poses a great risk (26.7 percent—which is less than half

of what it was 20 years ago).³⁶ In 2014, 33 percent of adults reported they believed regular marijuana use was harmful, compared to 50.4 percent in 2002 reporting the same.³⁷

Many women who use marijuana during pregnancy believe it is relatively safe.²⁴ They use marijuana to treat and alleviate symptoms of nausea and vomiting during pregnancy. Research on the prevalence of marijuana use by pregnant women is limited. The prevalence of self-reported prenatal marijuana use is between 2 percent and 5 percent in most studies.^{28,38,39,80} A recent study of 279,457 pregnant women in northern California, however, has reported prenatal marijuana use among pregnant women with severe nausea and vomiting at 2.3 percent, but 15 percent reported marijuana use for mild nausea and vomiting.⁴⁰ Another study found that 96 percent of mothers who continued using marijuana during pregnancy reported that they did so to treat nausea.³¹

Availability of and Access to Marijuana

There are multiple factors contributing to the perceived safety of marijuana use. As of June 25, 2019, 14 states and territories have approved adult-use marijuana/cannabis.⁴¹ A total of 34 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands have approved comprehensive, publicly available medical marijuana/cannabis programs.⁴¹

One study found that states that allow medical marijuana have seen increases in marijuana treatment admissions among pregnant women.⁴² The study also found there was no association between medical marijuana laws and the number of treatment admissions among non-pregnant women.⁴²

Studies have cited other factors—including uncertainty regarding adverse perinatal consequences, the perceived therapeutic effects of marijuana, and a lack of counseling from healthcare providers—as contributing to the perceived safety of marijuana use among pregnant women.²⁸

Further Contributing Risk Factors

While research on the risk factors associated with marijuana use among pregnant and postpartum women is limited, studies of other substance (e.g., alcohol, tobacco) use during pregnancy may inform our understanding of the complex interplay between contributing factors. Examples include:



Societal Factors:

- Policies that punish women for their substance use during pregnancy, including incarcerating women with SUDs, thereby limiting access to effective treatments^{43,44}

Community Factors:

- Limited access to contraception and subsequent unplanned pregnancy^{45,46,47}
- Limited access to health care^{47,48}

Relationship and Genetic Factors:

- Family history of alcohol and other substance misuse^{47,49}
- Physical, emotional, or sexual trauma as a child or adult^{45,50,51}
- Romantic partner who has a substance use disorder^{47,49}

Individual Factors:

- Personal history of alcohol and other substance misuse^{49,50,52,53,54}
- Personal history of inpatient treatment for substance or alcohol misuse and/or history of inpatient mental health treatment⁵⁵
- Post-traumatic stress disorder (often tied to adverse childhood experiences)^{56,57}
- Previous birth to a child adversely affected by substance use in utero^{47,58}

Most people who use marijuana start between the ages of 15 and 18. Among the 11.3 million women ages 12 and older who currently used marijuana in 2018, 3.4 million are between the ages of 18 and 25.² Women are at highest risk for developing SUDs during their reproductive years, especially between the ages of 18 and 29.⁵⁹

Potency and Content of Marijuana

Compared to the marijuana of 30 years ago, marijuana today is widely recognized as more potent.⁶⁰ The potency of marijuana has consistently increased, with THC levels rising from approximately 4 percent in 1995 to about 17 percent in 2017.^{60,61} Much of the evidence on the risks and adverse outcomes of marijuana use comes from older studies using less potent forms of marijuana.

The FDA does not regulate marijuana. Consequently, marijuana may include contaminants such as pesticides and fungus; however, most states with legal cannabis have implemented regulations about pesticide use. The FDA recommends that pregnant and breastfeeding women talk with a health care provider about the potential adverse health effects of marijuana use.¹⁸

The FDA has approved one cannabis-derived (CBD) drug product for the treatment of two forms of severe epilepsy, and three THC-related drug products for the treatment of nausea and vomiting caused by cancer chemotherapy or weight loss and poor appetite in patients with AIDS. These medications are only available with a prescription from a licensed healthcare provider.¹⁸

Harms Associated with Marijuana Use by Pregnant and Postpartum Women

Use of marijuana during and after pregnancy may pose risks to both mother and baby. Some research has documented effects of marijuana use during and after pregnancy, but much remains to be learned. Women should be aware of the realities and serious nature of these potential harms. Secondhand marijuana smoke contains THC and many of the toxic chemicals found in cigarette smoke. Exposure to secondhand marijuana smoke has been measured in nonsmokers.^{81,82} THC does accumulate in human breast milk, but its effect on infants remains

unknown. Because an infant's brain is continuing to develop, consuming THC in breast milk could affect brain development. Research is limited in this area, but it is a growing concern.

Birth Outcomes

Women who frequently or regularly use marijuana during their pregnancy may be more likely to experience worse birth outcomes, including low birth weight babies and preterm delivery, compared to pregnant women who do not use marijuana.

Studies show a clear association between prenatal marijuana use and low birth weight that is dependent on the mother's level of use.^{5,25,63} Preterm birth has been associated among women who used marijuana during pregnancy.^{83,84} Not all studies, however, have found this association between marijuana use and preterm birth, due to other confounding factors such as tobacco or other substance use.^{7,10,63} This is also likely a result of differing methodological approaches, including poor quantification of marijuana exposure and a lack of documentation for preterm birth in many studies. A systematic review and meta-analysis of maternal marijuana use and adverse neonatal outcomes found an association between heavy marijuana use and preterm birth.⁶

Breastfeeding Outcomes

Currently, there are insufficient data regarding the effects of marijuana use on breastfeeding infants. However, research suggests that chemicals from marijuana can be passed to infants through breast milk.⁶⁴ THC is stored in fat and is released slowly over time, meaning an infant can still be exposed through breast milk even after a mother stops using marijuana.^{38,63,64,65,66}

Additionally, studies show that women who smoke marijuana breastfeed for less time after birth.^{5,29,67} Breastfeeding is recommended by the American Academy of Pediatrics because it benefits a baby's immune system, including antibodies, immune factors, enzymes, and white blood cells, all of which protect against diseases and infections even after the child has weaned.⁶⁸

Childhood Outcomes

Research on this is limited (few longitudinal studies) and results are mixed because the women were also found to be using other substances (alcohol, tobacco). Also, data on these women were collected about 20 years ago, when potency of marijuana was much lower than what is used today. The relationship between marijuana use during pregnancy and other childhood outcomes is unclear. There is some evidence to suggest that prenatal exposure is linked to children's lower scores on tests of visual problem-solving, visual-motor coordination, and visual analysis.^{69,70,71,72} Prenatal marijuana exposure also is associated with decreased attention span and behavioral problems and is an independent predictor of marijuana use by 14 years of age.^{73,74,75} Effects of prenatal marijuana exposure on school performance remain unclear, with research having produced mixed results.^{5,76,77,78}

The following major medical associations have advised against marijuana use during pregnancy:

- **The American College of Obstetricians and Gynecologists (ACOG)** recommends women not use marijuana during pregnancy.²⁴
- The **American Academy of Pediatrics** released its first official guidelines in 2018 advising women who are pregnant or breastfeeding to avoid marijuana use because it is not safe for them or their children.²⁵
- The **National Council of State Boards of Nursing** states in its 2018 National Nursing Guidelines for Medical Marijuana that advanced practice registered nurses must consider the available scientific evidence around risks to particular groups of patients, including those of child-bearing age, pregnant women, and infants.⁶²

Cannabidiol Products

CBD is marketed as a variety of products including drugs, food, dietary supplements, cosmetics, pet food, and other animal health products.

Other than Epidiolex® to treat rare, severe forms of epilepsy, the FDA has not approved any other CBD products.

Some CBD products are being marketed with unproven medical claims. Misleading and false claims associated with CBD products may lead consumers to put off seeking important medical care, such as proper diagnosis, treatment, and supportive care.

There are many unanswered questions about the science, safety, and quality of products containing CBD. No compelling evidence shows that the use of CBD oil during pregnancy (or at other times) is beneficial.

The FDA is working toward learning more about CBD, including its effects⁷⁹:

- On the body, such as toxicity to the liver, when someone ingests CBD regularly over a long period of time
- From cumulative exposure across a broad range of consumer products
- On special populations (e.g., the elderly, children, adolescents, pregnant and breastfeeding women) or types of animals (e.g., species, breed, or class)

While some women seek to treat pregnancy-related nausea and vomiting by self-medicating with marijuana or cannabis products, **there is no evidence to show that marijuana helps manage morning sickness or that it is safe to use during pregnancy.**

- **Marijuana use is more common in pregnancies with severe nausea and vomiting.** Women experiencing severe symptoms are nearly four times as likely to use marijuana compared to women not experiencing nausea and vomiting. Those with mild symptoms are more than twice as likely to use marijuana as compared to women not experiencing nausea and vomiting.⁴⁰
- While there are FDA-approved cannabinoid medications to treat nausea and vomiting caused by cancer chemotherapy, **there have not been comparable tests done in women who are pregnant or breastfeeding.**^{18,24}

Reference List

1. Volkow, N. D., Han, B., Compton, W. M., & McCance-Katz, E. F. (2019). Self-reported medical and nonmedical cannabis use among pregnant women in the United States. *Journal of the American Medical Association, 322*(2), 167–169. doi:10.1001/jama.2019.7982
2. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. (2019). *Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health* (HHS Publication No. PEP19-5068, NSDUH Series H-54). Retrieved from <https://www.samhsa.gov/data>
3. Young-Wolff, K. C., Tucker, L. Y., Alexeeff, S., Armstrong, M. A., Conway, A., Weisner, C., & Goler, N. (2017). Trends in self-reported and biochemically tested marijuana use among pregnant females in California from 2009-2016. *Journal of the American Medical Association, 318*(24), 2490–2491. doi: 10.1001/jama.2017.17225
4. Corsi, D. J., Walsh, L., Weiss, D., Hsu, H., El-Chaar, D., Hawken, S., . . . Walker, M. (2019). Association between self-reported prenatal cannabis use and maternal, perinatal, and neonatal outcomes. *Journal of the American Medical Association, 322*(2), 145–152. doi: 10.1001/jama.2019.8734
5. National Academies of Sciences, Engineering, and Medicine. (2017). *The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research*. Washington, DC: The National Academies Press.
6. Conner, S. N., Bedell, V., Lipsey, K., Macones, G. A., Cahill, A. G., & Tuuli, M. G. (2016). Maternal marijuana use and adverse neonatal outcomes: A systematic review and meta-analysis. *Obstetrics & Gynecology, 128*: 713–723.
7. Gunn, J. K., Rosales, C. B., Center, K. E., Nuñez, A., Gibson, S. J., Christ, C., & Ehiri, J. E. (2016). Prenatal exposure to cannabis and maternal and child health outcomes: A systematic review and meta-analysis. *BMJ Open, 6*, e009986.
8. Kim, J., de Castro, A., Lendoiro, E., Cruz-Landeira, A., Lopez-Rivadulla, M., & Concheiro, M. (2018). Detection of in utero cannabis exposure by umbilical cord analysis. *Drug testing and analysis, 10*(4), 636–643. doi: 10.1002/dta.2307
9. Bertrand, K. A., Hanan, N. J., Honerkamp-Smith, G., Best, B. M., & Chambers, C. D. (2018). Marijuana use by breastfeeding mothers and cannabinoid concentrations in breast milk. *Pediatrics, 142*(3), e20181076. doi:10.1542/peds.2018-1076
10. Metz, T. D., & Stickrath, E. H. (2015). Marijuana use in pregnancy and lactation: A review of the evidence. *American Journal of Obstetrics and Gynecology, 213*(6), 761–778.

11. American Academy of Pediatrics. (2012). Breastfeeding and the use of human milk. *Pediatrics*, *129*(3), e827–e841. Retrieved from www.pediatrics.org/cgi/doi/10.1542/peds.2011-3552
12. Higgins, P. G., Clough, D. H., Frank, B., & Wallerstedt, C. (1995). Changes in health behaviors made by pregnant substance users. *International Journal of the Addictions*, *30*(10), 1323–1333. doi:10.3109/10826089509105137
13. Forray, A., Merry, B., Lin, H., Ruger, J. P., & Yonkers, K. A. (2015). Perinatal substance use: A prospective evaluation of abstinence and relapse. *Drug and Alcohol Dependence*, *150*, 147–155. doi:10.1016/j.drugalcdep.2015.02.027
14. Small, E. (2015). Evolution and classification of cannabis sativa (marijuana, hemp) in relation to human utilization. *The Botanical Review*, *81*(3), 189–294. doi:10.1007/s12229-015-9157-3
15. American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: American Psychiatric Association Publishing.
16. U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse. (2018). Marijuana as medicine. Retrieved from <https://www.drugabuse.gov/publications/drugfacts/marijuana-medicine>
17. U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse. (2019). What is marijuana? Retrieved from <https://www.drugabuse.gov/publications/research-reports/marijuana/what-marijuana>
18. U.S. Department of Health and Human Services, U.S. Food and Drug Administration. (2019). FDA regulation of cannabis and cannabis-derived products: Questions and answers. Retrieved from <https://www.fda.gov/news-events/public-healthfocus/fda-regulation-cannabis-and-cannabis-derived-products-questions-and-answers#cosmetics>
19. U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse. (2018). Marijuana. Retrieved from <https://www.drugabuse.gov/publications/researchreports/marijuana>
20. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. (2017). Key statistics from the National Survey of Family Growth: B listing. Retrieved from https://www.cdc.gov/nchs/nsfg/key_statistics/b.htm#birthsmothers
21. Population Reference Bureau. (2018). Glossary of demographic terms. Retrieved from <https://www.prb.org/glossary>
22. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. (2018). Selecting best-fit programs and practices: Guidance for substance misuse prevention practitioners. Retrieved from https://www.samhsa.gov/sites/default/files/ebp_prevention_guidance_document_241.pdf
23. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. (2018). Definition of policy. Retrieved from <https://www.cdc.gov/policy/analysis/process/definition.html>
24. American College of Obstetricians and Gynecologists. (2017). ACOG Committee Opinion No. 722: Marijuana use during pregnancy and lactation. *Obstetrics and Gynecology*, *130*, e205–9.
25. Ryan, S. A., Ammerman, S. D., O'Connor, M. E., American Academy of Pediatrics (AAP) Committee on Substance Use and Prevention, & AAP Section on Breastfeeding. (2018). Marijuana use during pregnancy and breastfeeding: Implications for neonatal and childhood outcomes. *Pediatrics*, *142*(3), e20181889

26. Vermont Department of Health. (2017). Marijuana use before, during, and after pregnancy: Vermont PRAMS 2009-2013. Retrieved from https://www.healthvermont.gov/sites/default/files/documents/2017/02/PRAMS_Marijuana_2009_2013_corrected.pdf
27. Ko, J. Y., Farr, S. L., Tong, V. T., Creanga, A. A., & Callaghan, W. M. (2015). Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. *American Journal of Obstetrics and Gynecology*, *213*(2), 201.
28. Bayrampour, H., Zahradnik, M., Lisonkova, S., & Janssen, P. (2019). Women's perspectives about cannabis use during pregnancy and the postpartum period: An integrative review. *Preventive Medicine*, *119*, 17–23.
29. Ko, J. Y., Tong, V. T., Bombard, J. M., Hayes, D. K., Davy, J., & Perham-Hester, K. A. (2018). Marijuana use during and after pregnancy and association of prenatal use on birth outcomes: A population-based study. *Drug and Alcohol Dependence*, *187*(1), 72–78.
30. Brown, Q. L., Sarvet, A. L., Shmulewitz, D., Martins, S. S., Wall, M. M., & Hasin, D. S. (2017). Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002-2014. *JAMA*, *317*(2), 207–209.
31. Mark, K., Gryczynski, J., Axenfeld, E., Schwartz, R. P., & Terplan, M. (2017). Pregnant women's current and intended cannabis use in relation to their views toward legalization and knowledge of potential harm. *Journal of Addiction Medicine*, *11*(3), 211–216.
32. Beatty, J. R., Svikis, D. S., & Ondersma, S. J. (2012). Prevalence and perceived financial costs of marijuana versus tobacco use among urban low-income pregnant women. *Addiction Research and Theory*, *3*(4). doi: 10.4172/2155-6105.1000135
33. Hasin, D. S. (2018). US epidemiology of cannabis use and associated problems. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology*, *43*(1), 195–212. doi: 10.1038/npp.2017.198
34. Chen, C. Y., Storr, C. L., & Anthony, J. C. (2009). Early-onset drug use and risk for drug dependence problems. *Addictive Behaviors*, *34*(3), 319–322.
35. Hasin, D. S., Kerridge, B. T., Saha, T. D., Huang, B., Pickering, R., Smith, S. M., Jung, J., Zhang, H., & Grant, B. F. (2016). Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *American Journal of Psychiatry*, *173*(6), 588–599.
36. U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse. (2018). *Monitoring the Future survey: High school and youth trends*. Retrieved from <https://www.drugabuse.gov/publications/drugfacts/monitoringfuture-survey-high-school-youth-trends>
37. Compton, W. M., Han, B., Jones, C. M., Blanco, C., & Hughes, A. (2016). Marijuana use and use disorders in adults in the USA, 2002-14: Analysis of annual cross-sectional surveys. *The Lancet Psychiatry*, *3*(10), 954–964. doi: 10.1016/S2215-0366(16)30208-5
38. Thompson, R., DeJong, K., & Lo, J. (2019). Marijuana use in pregnancy: A review. *Obstetrical & Gynecological Survey*, *74*(7), 415–428.
39. Roberson, E. K., Patrick, W. K., & Hurwitz, E. L. (2014). Marijuana use and maternal experiences of severe nausea during pregnancy in Hawaii. *Hawai'i Journal of Medicine and Public Health*, *73*(9), 283–287.

40. Young-Wolff, K. C., Sarovar, V., Tucker, L.-Y., Avalos, L. A., Conway, A., Armstrong, M. A., & Goler, N. (2018). Association of nausea and vomiting in pregnancy with prenatal marijuana use. *JAMA Internal Medicine, 178*(10), 1423–1424.
41. National Conference of State Legislatures. (2019). State medical marijuana laws. Retrieved from <http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx>
42. Meinhofer, A., Witman, A., Murphy, S., & Bao, Y. (2019). Medical marijuana laws are associated with increases in substance use treatment admissions by pregnant women. *Addiction, 114*(9), 1593–1601. doi:10.1111/add.14661
43. Roberts, S. C. M., Mericle, A. A., Subbaraman, M. S., Thomas, S., Treffers, R. D., Delucchi, K. L., & Kerr, W. C. (2019). State policies targeting alcohol use during pregnancy and alcohol use among pregnant women 1985 – 2016: Evidence from the Behavioral Risk Factor Surveillance System. *Women's Health Issues, 29*(3), 213–221. doi: 10.1016/j.whi.2019.02.001
44. American College of Obstetricians and Gynecologists. (2011). Substance abuse reporting and pregnancy: The role of the obstetrician–gynecologist. Committee Opinion No. 473. *Obstetrics and Gynecology, 117*, 200–201.
45. Astley, S. J., Bailey, D., Talbot, C., & Clarren, S. K. (2000). Fetal alcohol syndrome (FAS) primary prevention through FAS diagnosis: II. A comprehensive profile of 80 birth mothers of children with FAS. *Alcohol and Alcoholism, 35*(5), 509–519. doi: 10.1093/alcalc/35.5.509
46. Black, K. I., & Day, C. A. (2016). Improving access to long-acting contraceptive methods and reducing unplanned pregnancy among women with substance use disorders. *Substance Abuse: Research and Treatment, 10*(Supplement 1), 27–33.
47. Stratton, K., Howe, C., & Battaglia, F. C. (1996). *Fetal alcohol syndrome: Diagnosis, epidemiology, prevention, and treatment*. Washington, DC: The National Academies Press.
48. Astley, S. J., Bailey, D., Talbot, C., & Clarren, S. K. (2000). Fetal alcohol syndrome (FAS) primary prevention through FAS diagnosis: I. Identification of high-risk birth mothers through diagnosis of their children. *Alcohol and Alcoholism, 35*(5), 499–508. doi:10.1093/alcalc/35.5.499
49. Leonardson, G. R., Loudenburg, R., & Struck, J. (2007). Factors predictive of alcohol use during pregnancy in three rural states. *Behavioral and Brain Functions, 3*, 8. doi: 10.1186/1744-9081-3-8
50. Spears, G. V., Stein, J. A., & Koniak-Griffin, D. (2010). Latent growth trajectories of substance use among pregnant and parenting adolescents. *Psychology of Addictive Behaviors, 24*(2), 322–332. doi: 10.1037/a0018518
51. Skagerstrom, J., Chang, G., & Nilsen, P. (2011). Predictors of drinking during pregnancy: A systematic review. *Journal of Women's Health, 20*(6), 901–913. doi: 10.1089/jwh.2010.2216
52. Bobo, J. K., Klepinger, D. H., & Dong, F. B. (2007). Identifying social drinkers likely to consume alcohol during pregnancy: Findings from a prospective cohort study. *Psychological Reports, 101*(3), 857–870. doi:10.2466/pr0.101.3.857-870
53. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. (2002). Alcohol use among women of childbearing age—United States, 1991-1999. *Morbidity and Mortality Weekly Report: Surveillance Summaries, 51*(13), 273–276.

54. U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism. (2000). *10th special report to the U.S. Congress on alcohol and health*. Washington, DC: U.S. Department of Health and Human Services.
55. Project CHOICES Intervention Research Group. (2003). Reducing the risk of alcohol-exposed pregnancies: A study of a motivational intervention in community settings. *Pediatrics*, *111*(5, Pt. 2), 1131–1135.
56. Najavits, L. M., Weiss, R. D., & Shaw, S. R. (1997). The link between substance abuse and posttraumatic stress disorder in women: A research review. *The American Journal on Addictions*, *6*(4), 273–283.
57. Bailey, K., Trevillion, K., & Gilchrist, G. (2019). What works for whom and why: A narrative systematic review of interventions for reducing post-traumatic stress disorder and problematic substance use among women with experiences of interpersonal violence. *Journal of Substance Abuse Treatment*, *99*, 88–103.
58. Kvigne, V. L., Leonardson, G. R., Borzelleca, J., Brock, E., Neff-Smith, M., & Welty, T. K. (2003). Characteristics of mothers who have children with fetal alcohol syndrome or some characteristics of fetal alcohol syndrome. *The Journal of the American Board of Family Practice*, *16*(4), 296–303.
59. Compton, W. M., Thomas, Y. F., Stinson, F. S., & Grant, B. F. (2007). Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Archives of General Psychiatry*, *64*(5), 566–576. doi: 10.1001/archpsyc.64.5.566
60. ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., & Church, J. C. (2016). Changes in cannabis potency over the last 2 decades (1995–2014): Analysis of current data in the United States. *Biological Psychiatry*, *79*(7), 613–619. doi:10.1016/j.biopsych.2016.01.004
61. Chandra, S., Radwan, M. M., Majumdar, C. G., Church, J. C., Freeman, T. P., & ElSohly, M. A. (2019). New trends in cannabis potency in USA and Europe during the last decade (2008–2017). *European Archives of Psychiatry and Clinical Neuroscience*, *269*(1), 5–15. doi: 10.1007/s00406-019-00983-5
62. National Council of State Boards of Nursing. (2018). The NCSBN national nursing guidelines for medical marijuana. *Journal of Nursing Regulation*, *9*(Suppl. 2), S1–S60.
63. Metz, T. D., & Borgelt, L. M. (2018). Marijuana use in pregnancy and while breastfeeding. *Obstetrics and Gynecology*, *132*(5), 1198–1210.
64. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. (2018). What you need to know about marijuana use and pregnancy. Retrieved from <https://www.cdc.gov/marijuana/factsheets/pregnancy.htm>
65. Hutchings, D. E., Martin, B. R., Gamagaris, Z., Miller, N., & Fico, T. (1989). Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. *Life Sciences*, *44*(11), 697–701. doi: 10.1016/0024-3205(89)90380-9
66. Fernandez-Ruiz, J., Gomez, M., Hernandez, M., de Miguel, R., & Ramos, J. A. (2004). Cannabinoids and gene expression during brain development. *Neurotoxicity Research*, *6*(5), 389–401.

67. Crume, T. L., Juhl, A. L., Brooks-Russell, A., Hall, K. E., Wymore, E., & Borgelt, L. M. (2018). Cannabis use during the perinatal period in a state with legalized recreational and medical marijuana: The association between maternal characteristics, breastfeeding patterns, and neonatal outcomes. *The Journal of Pediatrics*, *197*, 90–96. doi: 10.1016/j.jpeds.2018.02.005
68. American Academy of Pediatrics. (2016). Breastfeeding Benefits Your Baby's Immune System. Retrieved from <https://www.healthychildren.org/English/ages-stages/baby/breastfeeding/Pages/Breastfeeding-Benefits-Your-Babys-Immune-System.aspx>
69. Fried, P. A., Watkinson, B., & Gray R. (2003). Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. *Neurotoxicology and Teratology*, *25*(4), 427–436.
70. Chandler, L. S., Richardson, G. A., Gallagher, J. D., & Day, N. L. Prenatal exposure to alcohol and marijuana: Effects on motor development of preschool children. (1996). *Alcoholism: Clinical and Experimental Research*, *20*(3), 455–461.
71. Fried, P. A., & Watkinson, B. (2001). Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marijuana. *Neurotoxicology and Teratology*, *23*(5), 421–430.
72. Day, N. L., Goldschmidt, L., & Thomas, C. A. (2006). Prenatal marijuana exposure contributes to the prediction of marijuana use at age 14. *Addiction*, *101*(9), 1313–1322. doi: 10.1111/j.1360-0443.2006.01523
73. Goldschmidt, L., Day, N. L., & Richardson, G. A. (2000). Effects of prenatal marijuana exposure on child behavior problems at age 10. *Neurotoxicology and Teratology*, *22*(3), 325–336.
74. Fried, P. A., O'Connell, C. M., & Watkinson, B. (1992). 60- and 72-month follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol: Cognitive and language assessment. *Journal of Developmental and Behavioral Pediatrics*, *13*(6), 383–391.
75. Fried, P. A., Watkinson, B., & Siegel, L. S. (1997). Reading and language in 9- to 12-year olds prenatally exposed to cigarettes and marijuana. *Neurotoxicology and Teratology*, *19*(3), 171–183. doi: 10.1016/S0892-0362(97)00015-9
76. Goldschmidt, L., Richardson, G. A., Cornelius, M. D., & Day, N. L. (2004). Prenatal marijuana and alcohol exposure and academic achievement at age 10. *Neurotoxicology and Teratology*, *26*(4), 521–532. doi: 10.1016/j.ntt.2004.04.003
77. Linn, S., Schoenbaum, S. C., Monson, R. R., Rosner, R., Stubblefield, P. C., & Ryan, K. J. (1983). The association of marijuana use with outcome of pregnancy. *American Journal of Public Health*, *73*(10), 1161–1164. doi: 10.2105/AJPH.73.10.1161
78. van Gelder, M. M., Reefhuis, J., Caton, A. R., Werler, M. M., Druschel, C. M., & Roeleveld, N. (2009). Maternal periconceptional illicit drug use and the risk of congenital malformations. *Epidemiology*, *20*(1), 60–66. doi: 10.1097/EDE.0b013e3181818e5930
79. U.S. Food and Drug Administration. (2019). What You Need to Know (And What We're Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD. Retrieved from <https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis>

80. Jarlenski, M., Koma, J. W., Zank, J., Bodnar, L. M., Bogen, D. L., & Change, J. C. (2017). Trends in perception of risk of regular marijuana use among US pregnant and nonpregnant reproductive-aged women. *American Journal of Obstetrics and Gynecology*, 217(6): 705–707.
81. Cone, E. J., Bigelow, G. E., Herrmann, E. S., Mitchell, J. M., LoDico, C., Flegel, R., & Vandrey, R. (2015) Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results. *Journal of Analytical Toxicology*, 39(1): 1–12.
82. Cone, E. J., Bigelow, G. E., Herrmann, E. S., Mitchell, J. M., LoDico, C., Flegel, R., & Vandrey, R. (2015). Exposure to secondhand cannabis smoke. III. Oral fluid and blood drug concentrations and corresponding subjective effects. *Journal of Analytical Toxicology*, 39(7): 497–509.
83. Leemaqz, S. Y., Dekker, G. A., McCowan, L. M., Kenny, L. C., Myers, J. E., Simpson, N. A. B., Poston, L., & Roberts, C. T. (2016). Maternal marijuana use has independent effects on risk for spontaneous preterm birth but not other common late pregnancy complications. *Reproductive Toxicology*, 62: 77–86.
84. Dekker, G. A., Lee, S. Y., North, R. A., McCowan, L. M., Simpson, N. A. B., & Roberts, C. T. (2012). Risk factors for preterm birth in an international prospective cohort of nulliparous women. *PLoS ONE*, 7(7): 1–9.

WHAT RESEARCH TELLS US

Effective Practices to Prevent Substance Use During Pregnancy



When examining program effectiveness, it is often difficult to isolate programs focused exclusively on preventing marijuana use. Women who use marijuana during pregnancy may also use other substances, such as tobacco, alcohol, or illicit drugs. Sometimes women who use marijuana during pregnancy also have experienced poverty, poor diet, interpersonal violence, or intergenerational trauma, any of which can influence pregnancy outcomes.¹ Due to these factors, very few studies focus solely on preventing perinatal marijuana use. The best evidence available consists of prevention research on other substances.

The risk factors and issues surrounding other types of substance misuse during pregnancy may be similar to those surrounding marijuana use during pregnancy. This chapter focuses on a broader evidence base that includes studies of programs and practices designed to prevent substance misuse including, but not limited to, marijuana. Evidence-based programs are those that have demonstrated effectiveness in preventing or reducing substance misuse and its consequences.

Evidence of effectiveness falls along a continuum, from strong to weak. Strong evidence of a program or practice's effectiveness comes from strong evaluation studies. Evidence is most compelling when studies of a practice or program are scientifically rigorous, numerous, and include testing among various populations and settings.²

Prevention of Unintended Pregnancy

In 2011, 45 percent of pregnancies in the United States were unintended.³ Women may continue to use substances without realizing they are pregnant. They may be unprepared or unable to stop using substances when they become pregnant.³

There is abundant evidence on the effectiveness of various contraception methods that are effective among women who frequently misuse substances or have a substance use disorder (SUD).⁴ Women who are using substances and do not wish to become pregnant should consider using one of these methods. The evidence for contraception methods is not included in this chapter.

Criteria for Assessing the Evidence

An expert panel developed the following criteria to guide the selection of evidence-based practices featured in this chapter. According to the expert panel, an evidence-based practice must:

- Be supported by evaluation studies that, at a minimum,
 1. Employ a quasi-experimental research design with equivalent intervention and comparison groups;
 2. Use methods to isolate the effects of the intervention and rule out alternative explanations for the outcomes found; and
 3. Demonstrate prevention of, or reduction in, marijuana or other substance use prior to, during, or following pregnancy.
- Include sound theory or logic that connects the evidence-based practice to the prevention of marijuana or other substance misuse (including alcohol and tobacco) prior to, during, or following pregnancy
- Be incorporated into one or more programs that address risk or protective factors for marijuana or other substance misuse prior to, during, or following pregnancy



Screening, Brief Intervention, and Referral to Treatment (SBIRT)

Primary care and obstetrical providers often use screening, brief intervention, and referral to treatment (SBIRT) to identify alcohol and tobacco use among pregnant women. The U.S. Preventive Services Task Force recommends the use of SBIRT to address substance misuse, as do professional societies such as ACOG.⁵⁻⁷

Using a validated screening questionnaire, SBIRT helps identify women who misuse marijuana or have cannabis use disorder. Simply asking about alcohol and other substance use can also result in behavior change.⁸ When a healthcare provider recognizes that a woman is engaging in marijuana or other substance misuse, the woman receives brief counseling (5–10 minutes) from a trained prenatal provider.

During this brief intervention, prenatal providers often use motivational interviewing techniques that help women determine their interest in making life changes through individualized goal setting.⁹ Women whose screening results indicate that they have cannabis use disorder—and who have accepted they are in need of treatment—will receive a referral from the provider for treatment.

Since SBIRT studies that focus on marijuana use and pregnant women are limited, information from studies of other substances such as tobacco, alcohol, and illicit drugs contributes to the understanding of what works.¹⁰ Computer-based screening and brief intervention have had positive initial acceptability by women and are associated with healthy pregnancy outcomes.^{11, 12}

Outcomes Associated with SBIRT



- Decreases in alcohol consumption during pregnancy¹¹⁻¹⁵
- Decreases in alcohol-exposed pregnancies¹¹⁻¹⁵
- Decreases in preterm labor rates¹⁶⁻²⁰



- Decreases in neonatal intensive care admissions¹⁶⁻²⁰
- Increases in infant birthweight¹⁶⁻²⁰
- Decreases in number of infants exposed to maternal illicit drug use¹⁶⁻²⁰



- Decreases in number of heavy drinking days during postpartum period²¹

Integrated Clinics for Pregnant and Parenting Women

Integrated clinics, sometimes referred to as integrated programs, are co-located health promotion and substance misuse prevention providers for pregnant and parenting women and their children. These clinics are “one-stop shops” that typically offer prenatal care, general primary care, counseling for mental and substance use disorders, services for parenting and child development, and other necessary supports (e.g., housing, transportation, legal aid, case management).

Such supports are designed to promote health equity by helping women who may be at increased risk for poor pregnant and postpartum outcomes—due, for example, to limited income and educational opportunities, mental illness, domestic violence, or sexual or other trauma—access the critical care that is readily available to other women who do not face such challenges.^{22, 23}

Although the integrated clinic model has been around since the 1970s, the majority of states lack these clinics. Integrated clinics can function successfully with limited funding in existing primary care clinics via a person-centered medical home model.²³

According to the Institute for Healthcare Improvement, the maternity medical home model adopts medical home principles to perinatal care and also incorporates several key elements that address risk factors and behaviors, such as substance misuse, that can affect a mother’s health and birth outcomes.

Key elements included in the maternity medical home model include:²⁴

- A standardized risk assessment to identify a woman’s needs
- A focus on first-trimester entry into prenatal care
- Care coordination to ensure that a woman receives all needed services during pregnancy
- Standardized care pathways to target common risk factors for poor birth outcomes and ensure each woman receives all recommended care

- Enhanced access such as expanded hours and improved ability to contact providers
- Person-centered care, including shared decision making about key aspects of perinatal care (such as where and how labor and delivery take place)

The medical home model includes:²⁵

- A personal physician
- A physician-directed medical practice
- Whole-person orientation
- Coordinated and integrated care
- A quality and safety focus
- Enhanced access to care
- Payment that recognizes the value offered to individuals by the model

Evidence indicates that integrated clinics improve prenatal appointment attendance, birth outcomes, parenting, and overall maternal mental health.²⁶⁻³¹

Outcomes Associated with Integrated Clinics



- Reductions in maternal substance misuse prior to, during, and after pregnancy²⁶⁻²⁹
- Increased engagement in treatment and prenatal care for women who use marijuana²⁸



- Improvements in infant outcomes and child welfare³⁰



- Improved attendance for postpartum appointments³¹
- Decreased rates of breastfeeding discontinuation³¹
- Increased use of effective postpartum contraception, including long-acting reversible contraception (LARC)³¹

Health Communication Campaigns to Change Behaviors

Health communication campaigns seek to promote change or produce outcomes among a certain population or the general public. Health communication campaigns can:³²

- Provide direct information to those who are expected to adopt a healthy behavior or change an unhealthy behavior
- Use multiple communications methodologies such as social media, television, radio, and appointments with healthcare professionals and outreach workers
- Influence the adoption of healthy behaviors by changing knowledge and beliefs about behaviors, perceived social norms, and actual skills and confidence in skills

There is limited research on the effectiveness of communication campaigns to prevent or reduce marijuana use among pregnant or postpartum women. However, it is possible to extrapolate from evaluations of communication campaigns that focus on other substances and target the general population or other audience segments.

For example, health communication campaigns have been effective in changing beliefs about tobacco use, preventing the initiation of tobacco use, and promoting tobacco cessation.³³ Campaigns have been especially effective in reducing tobacco use among youth. These campaigns use commercial marketing tactics, including branding of messages, images, and warning labels, to refute pro-substance influences and increase pro-health messages and influences.

Successful health communication education campaigns require a great deal of thoughtful planning on the front end. A recent study reports that states using more aggressive negative messaging regarding alcohol use during pregnancy in such campaigns actually saw worse pregnancy outcomes and higher costs.^{34, 35}

To be effective, key messages should provide accuracy and consistency without shaming or blaming women.³⁶ Messaging that is more likely to be effective will target the reasons women use marijuana during pregnancy, explain the known and possible risks of marijuana use during pregnancy, and promote the use of medications known to be safe in pregnancy.

Outcomes Associated with Health Communication Campaigns



Outcomes of campaigns implemented as part of comprehensive tobacco control programs:

- Prevention of tobacco smoking initiation in youth³⁷
- Promotion of tobacco smoking cessation in adults³⁷⁻³⁹
- Reduction in relapse rates among individuals who have quit smoking⁴⁰



Campaigns that elicit negative emotions through graphic and personal portrayals of the health consequences of tobacco use can lead to:

- Motivation for smokers to quit³⁷⁻³⁹
- Reduction in tobacco use among youth and young adults^{33, 41}

Social Norms

Social norms are implicit or explicit rules about which behaviors are acceptable in society. Social norms change is an opportunity to change behavior on a societal level.⁴² By changing public perception, public health campaigns can “de-normalize” risky behavior. Most work on social norms change has been done with tobacco, starting with the Surgeon General’s 1964 report.⁴³

Contingency Management for Reducing Use

Contingency management is one of the most effective approaches to treating SUDs. Typically implemented in clinical settings, contingency management relies on “operant conditioning,” or providing rewards to individuals based on their level of behavioral change. In the case of marijuana use, the behavioral change would be periods of abstinence.

When implementing contingency management, the clinician will:^{44, 45}

1. Arrange for regular testing to ensure that the individual is abstaining from substance use.
2. Provide agreed-upon and tangible rewards, such as vouchers, when the individual abstains.
3. Withhold the reward or incentive from the individual when substance use is detected.
4. Assist the individual in establishing alternate and healthier activities to replace the rewards derived from substance use.

Many programs use this practice during pregnancy to promote healthy prenatal behavior in women, such as reducing or quitting substance misuse.^{46, 47} Contingency management has proven effective for helping pregnant women quit smoking.⁴⁸ It is also effective for helping women in general abstain from cocaine, tobacco, and heroin.^{47, 49, 50}

A recent systematic review of evaluation research shows that incentives for tobacco smoking cessation may be especially effective for pregnant women.⁵¹ While no studies focus on the effectiveness of contingency management to prevent marijuana use in pregnancy, one study reveals the potential of the practice to decrease marijuana use for a set amount of time in young adults (ages 18–25 years) not seeking to discontinue long-term use.⁵² This study is particularly relevant, as 7.5 million women between the ages of 18 and 25 use marijuana and are in the child-bearing age range.

Outcomes Associated with Contingency Management

Pregnant and postpartum women who are introduced to contingency management are more likely to:



- Be willing and able to engage in SUD treatment⁴⁷



- Be willing to quit or temporarily stop smoking tobacco products during pregnancy and the postpartum period⁴⁸



- Reduce use of illicit drugs such as cocaine and heroin^{47, 49, 50}

Postpartum Home Visits by Health Professionals

The postpartum period can be a risky time for women to relapse and engage in substance misuse. This is a time when women experience the loss of the social and medical support they received during their pregnancy. Approximately 1 in 9 women experience postpartum depression.⁵³ Women face the challenges of caring for a helpless newborn while simultaneously struggling to heal their own bodies. These stressors may be risk factors for marijuana misuse.

Further, breastfeeding mothers are at risk for passing chemical components of marijuana to their infants.⁵⁴ Being under the effect of marijuana may impact child care duties. These factors can lead to infant neglect and harm.⁵⁵

Several practices help women cope with challenges in the postpartum period. Of these, one of the most studied is home visitation. The Health Resources and Services Administration (HRSA) and other public and private organizations provide support for home visitation programs. Home visitation programs can include help from health, social service, and child development professionals. Families that elect to participate receive regular, planned home visits during which they learn family management and childcare strategies that are likely to improve family functioning and child health outcomes.

According to HRSA, home visits may include:

- Supporting preventive health and prenatal practices
- Advising mothers on how best to breastfeed and care for their babies
- Helping parents understand child development milestones and behaviors
- Promoting parents' use of praise and other positive parenting techniques
- Working with mothers to set goals for the future, such as continuing their education or finding employment and childcare solutions

Outcomes Associated with Home Visiting Programs



- Improvement in infant and child health⁵⁶⁻⁶¹
- Reduction in substance misuse among children as they grow into adolescence and young adulthood⁶²⁻⁶⁴
- Reduction in child abuse and neglect^{65, 66}
- Improvement in child social and emotional development^{67, 68}
- Improvement in child school readiness^{67, 68}



- Improvement in maternal health⁵⁶⁻⁶¹
- Linkages and referrals to appropriate social supports and resources for the family⁶⁹
- Improvement in family economic self-sufficiency⁷⁰
- Increase in positive parenting practices^{67, 71}

Policies to Prevent and Reduce Marijuana Use

Concerns about the implementation of punitive strategies may deter women from seeking health care during and after pregnancy.^{72, 73}

The evidence shows that policies can prevent the initiation of substance misuse and reduce current adolescent use.⁷⁴⁻⁷⁸ Initiation of marijuana use in adolescence is a risk factor for marijuana use during pregnancy. Thus, preventing marijuana use among adolescents is one method for reducing marijuana use among pregnant women.

Much of the research concerning policies to reduce substance use in adolescent populations focuses on alcohol use. There is little research on the impact of marijuana policies. Implementation and evaluation of policies designed to prevent and reduce underage drinking and its associated consequences offer some guidance that may be applicable to preventing or reducing marijuana use during adolescence.

Lawmakers have developed, enacted, and applied policy strategies that target society- and community-level influences to reduce underage drinking and its associated consequences. These strategies include raising the minimum legal drinking age, setting a lower blood alcohol concentration (BAC) limit for young drivers, and limiting commercial and social access to alcohol.

Outcomes Associated with Policies to Reduce Underage Drinking



Policy

Increase the price through excise taxes and other methods

Outcome

Reductions in:

- Underage consumption⁷⁴⁻⁷⁸
- Consumption frequency⁷⁴⁻⁷⁸
- Amount consumed⁷⁴⁻⁷⁸
- Motor vehicle fatalities^{76, 79-81}
- Occurrences of driving while intoxicated^{76, 79-81}



Policy

Provide deterrents to using or incentives for not using, such as driver's license suspension following an offense or reducing the BAC limit for young people

Outcome

Reductions in:

- Minors in possession violations^{85, 86}
- Traffic deaths^{87, 88}



Policy

Restrict use and sale of alcohol at youth and community events

Outcome

Reductions in:

- Underage consumption⁸²⁻⁸⁴
- Negative social and legal consequences of underage consumption⁸²⁻⁸⁴



Policy

Restrict advertising to minors

Outcome

Reductions in:

- Youth traffic fatalities⁸⁹
- Alcohol consumption⁹⁰
- Occurrences of binge drinking⁹⁰

Reference List

1. Corsi, D. J., Walsh, L., Weiss, D., Hsu, H., El-Chaar, D., Hawken, S., . . . Walker, M et al. (2019). Association between self-reported prenatal cannabis use and maternal, perinatal, and neonatal outcomes. *Journal of the American Medical Association*, 322(2), 145–152. doi: 10.1001/jama.2019.8734
2. U.S. Department of Health & Human Services, Substance Abuse and Mental Health Services Administration. (2018). Selecting best-fit programs and practices: Guidance for substance misuse prevention practitioners. Retrieved from https://www.samhsa.gov/sites/default/files/ebp_prevention_guidance_document_241.pdf
3. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. (2018). Unintended pregnancy prevention. Retrieved from <https://www.cdc.gov/reproductivehealth/contraception/unintendedpregnancy/index.htm>
4. Terplan, M., Hand, D. J., Hutchinson, M., Salisbury-Afshar, E., & Heil, S. H. (2015). Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review. *Preventive Medicine*, 80, 23–31. doi: 10.1016/j.ypmed.2015.04.008
5. U.S. Preventive Services Task Force (2009). Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Annals of Internal Medicine*, 150(8), 551–555. doi: 10.7326/0003-4819-150-8-200904210-00009
6. Jonas, D. E., Garbutt, J. C., Amick, H. R., Brown, J. M., Brownley, K. A., Council, C. L., . . . Harris, R. P. (2012). Behavioral counseling after screening for alcohol misuse in primary care: A systematic review and meta-analysis for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*, 157(9), 645–654. doi: 10.7326/0003-4819-157-9-201211060-00544
7. American College of Obstetricians and Gynecologists. (2008). ACOG Committee Opinion No. 422: At-risk drinking and illicit drug use: Ethical issues in obstetric and gynecologic practice. *Obstetrics and Gynecology*, 112(6), 1449–1460. doi: 10.1097/AOG.0b013e318192499b
8. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. (1999). Enhancing motivation for change in substance abuse treatment (HHS Publication No. [SMA] 13-4212). Retrieved from <https://store.samhsa.gov/system/files/sma13-4212.pdf>
9. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Substance Abuse and Mental Health Services Administration and SAMHSA- HRSA Center for Integrated Health Solutions. (n.d.). Motivational interviewing. Retrieved from <https://www.integration.samhsa.gov/clinical-practice/motivational-interviewing>
10. Tanner-Smith, E. E., & Lipsey, M. W. (2015). Brief alcohol interventions for adolescents and young adults: A systematic review and meta-analysis. *Journal of Substance Abuse Treatment*, 51, 1–18. doi: 10.1016/j.jsat.2014.09.001
11. Chang, G., Wilkins-Haug, L., Berman, S., & Goetz, M. A. (1999). Brief intervention for alcohol use in pregnancy: A randomized trial. *Addiction*, 94(10), 1499–1508.
12. Chang, G., McNamara, T. K., Orav, E. J., Koby, D., Lavigne, A., Ludman, B., . . . Wilkins-Haug, L. (2005). Brief intervention for prenatal alcohol use: A randomized trial. *Obstetrics and Gynecology*, 105(5, Pt. 1), 991–998. doi: 10.1097/01.AOG.0000157109.05453.84

13. O'Connor, M. J., & Whaley, S. E. (2007). Brief intervention for alcohol use by pregnant women. *American Journal of Public Health, 97*(2), 252–258.
14. Montag, A. C., Brodine, S. K., Alcaraz, J. E., Clapp, J. D., Allison, M. A., Calac, D. J., . . . Chambers, C. D. (2015). Effect of depression on risky drinking and response to a screening, brief intervention, and referral to treatment intervention. *American Journal of Public Health, 105*(8), 1572–1576. doi: 10.2105/AJPH.2015.302688
15. Montag, A. C., Brodine, S. K., Alcaraz, J. E., Clapp, J. D., Allison, M. A., Calac, D. J., . . . Chambers, C. D. (2015). Preventing alcohol-exposed pregnancy among an American Indian/Alaska Native population: Effect of a screening, brief intervention, and referral to treatment intervention. *Alcoholism: Clinical and Experimental Research, 39*(1), 126–135. doi: 10.1111/acer.12607
16. Farr, S. L., Hutchings, Y. L., Ondersma, S. J., & Creanga, A. A. (2014). Brief interventions for illicit drug use among peripartum women. *American Journal of Obstetrics and Gynecology, 211*(4), 336–343. doi: 10.1016/j.ajog.2014.04.005
17. Ondersma, S. J., Svikis, D. S., Thacker, L. R., Beatty, J. R., & Lockhart, N. (2014). Computer-delivered screening and brief intervention (e-SBI) for postpartum drug use: A randomized trial. *Journal of Substance Abuse Treatment, 46*(1), 52–59. doi: 10.1016/j.jsat.2013.07.013
18. Ondersma, S. J., Svikis, D. S., & Schuster, C. R. (2007). Computer-based brief intervention: A randomized trial with postpartum women. *American Journal of Preventive Medicine, 32*(3), 231–238.
19. Mullins, S. M., Suarez, M., Ondersma, S. J., & Page, M. C. (2004). The impact of motivational interviewing on substance abuse treatment retention: A randomized control trial of women involved with child welfare. *Journal of Substance Abuse Treatment, 27*(1), 51–58. doi: 10.1016/j.jsat.2004.03.010
20. Alemi, F., Stephens, R. C., Javalghi, R. G., Dyches, H., Butts, J., & Ghadiri, A. (1996). A randomized trial of a telecommunications network for pregnant women who use cocaine. *Medical Care, 34*(Suppl. 10), OS10–OS20.
21. Fleming, M. F., Lund, M. R., Wilton, G., Landry, M., & Scheets, D. (2008). The Healthy Moms Study: The efficacy of brief alcohol intervention in postpartum women. *Alcoholism: Clinical and Experimental Research, 32*(9), 1600–1606. doi: 10.1111/j.1530-0277.2008.00738
22. Le, T. L., Kenaszchuk, C., Milligan, K., & Urbanoski, K. (2019). Levels and predictors of participation in integrated treatment programs for pregnant and parenting women with problematic substance use. *BMC Public Health, 19*(1), 154. doi: 10.1186/s12889-019-6455-4
23. Ordean, A., & Kahan, M. (2011). Comprehensive treatment program for pregnant substance users in a family medicine clinic. *Canadian Family Physician, 57*(11), e430–e435.
24. Jeff Rakover. (2016, March 22). The maternity medical home: The chassis for a more holistic model of pregnancy care? [Web log post]. Retrieved from http://www.ihl.org/communities/blogs/_layouts/15/ihl/community/blog/itemview.aspx?List=7d1126ec-8f63-4a3b-9926-c44ea3036813&ID=222

25. American Academy of Family Physicians, American Academy of Pediatrics, American College of Physicians, and American Osteopathic Association. (2007). Joint principles of the patient-centered medical home. Retrieved from American Academy of Family Physicians website: https://www.aafp.org/dam/AAFP/documents/practice_management/pcmh/initiatives/PCMHJoint.pdf
26. Milligan, K., Niccols, A., Sword, W., Thabane, L., Henderson, J., Smith, A., & Liu, J. (2010). Maternal substance use and integrated treatment programs for women with substance abuse issues and their children: A meta-analysis. *Substance Abuse Treatment, Prevention, and Policy*, 5, 21. doi: 10.1186/1747-597X-5-21
27. Milligan, K., Niccols, A., Sword, W., Thabane, L., Henderson, J., & Smith, A. (2011). Birth outcomes for infants born to women participating in integrated substance abuse treatment programs: A meta-analytic review. *Addiction Research and Theory*, 19(6), 542–555.
28. Milligan, K., Niccols, A., Sword, W., Thabane, L., Henderson, J., & Smith, A. (2010). Length of stay and treatment completion for mothers with substance abuse issues in integrated treatment programmes. *Drugs: Education, Prevention and Policy*, 18(3), 219–227.
29. Niccols, A., Milligan, K., Sword, W., Thabane, L., Henderson, J., & Smith, A. (2012). Integrated programs for mothers with substance abuse issues: A systematic review of studies reporting on parenting outcomes. *Harm Reduction Journal*, 9, 14. doi: 10.1186/1477-7517-9-14
30. Niccols, A., Milligan, K., Smith, A., Sword, W., Thabane, L., & Henderson, J. (2012). Integrated programs for mothers with substance abuse issues and their children: A systematic review of studies reporting on child outcomes. *Child Abuse & Neglect*, 36(4), 308–322.
31. Ashley, O. S., Marsden, M. E., & Brady, T. M. (2003). Effectiveness of substance abuse treatment programming for women: A review. *The American Journal of Drug and Alcohol Abuse*, 29(1), 19–53.
32. Institute of Medicine. (2002). *Speaking of health: Assessing health communication strategies for diverse populations*. Washington, DC: The National Academies Press.
33. U.S. Department of Health and Human Services, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. (2012). Preventing tobacco use among youth and young adults: A report of the Surgeon General. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK99237>
34. Subbaraman, M. S., Thomas, S., Treffers, R., Delucchi, K., Kerr, W. C., Martinez, P., & Roberts, S. C. M. (2018). Associations between state-level policies regarding alcohol use among pregnant women, adverse birth outcomes, and prenatal care utilization: Results from 1972 to 2013 Vital Statistics. *Alcoholism: Clinical and Experimental Research*, 42(8), 1511–1517. doi: 10.1111/acer.13804
35. Subbaraman, M. S., & Roberts, S. C. M. (2019). Costs associated with policies regarding alcohol use during pregnancy: Results from 1972-2015 Vital Statistics. *PLOS One*, 14(5), e0215670. doi: 10.1371/journal.pone.0215670
36. France, K. E., Donovan, R. J., Bower, C., Elliott, E. J., Payne, J. M., D’Antoine, H., & Bartu, A. E. (2014). Messages that increase women’s intentions to abstain from alcohol during pregnancy: Results from quantitative testing of advertising concepts. *BMC Public Health*, 14, 30. doi: 10.1186/1471-2458-14-30

37. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. (2008). The role of the media in promoting and reducing tobacco use (NIH Publication No. 07- 6242). Retrieved from https://cancercontrol.cancer.gov/brp/tcrb/monographs/19/m19_complete.pdf
38. Durkin, S., Brennan, E., & Wakefield, M. (2012). Mass media campaigns to promote smoking cessation among adults: An integrative review. *Tobacco Control, 21*(2), 127–138. doi: 10.1136/tobaccocontrol-2011-050345
39. Farrelly, M. C., Duke, J. C., Davis, K. C., Nonnemaker, J. M., Kamyab, K., Willett, J. G., & Juster, H. R. (2012). Promotion of smoking cessation with emotional and/or graphic antismoking advertising. *American Journal of Preventive Medicine, 43*(5), 475–482. doi: 10.1016/j.amepre.2012.07.023
40. Wakefield, M. A., Bowe, S. J., Durkin, S. J., Yong, H. H., Spittal, M. J., Simpson, J. A., & Borland, R. (2013). Does tobacco-control mass media campaign exposure prevent relapse among recent quitters? *Nicotine & Tobacco Research, 15*(2), 385–392. doi: 10.1093/ntr/nts134
41. McAfee, T., Davis, K. C., Alexander, R. L., Jr., Pechacek, T. F., & Bunnell, R. (2013). Effect of the first federally funded US antismoking national media campaign. *The Lancet, 382*(9909), 2003–2011. doi: 10.1016/S0140-6736(13)61686-4
42. Perkins, H. W. (Ed.). (2003). *The social norms approach to preventing school and college age substance abuse: A handbook for educators, counselors, and clinicians*. San Francisco, CA: Jossey-Bass.
43. U.S. Department of Health and Human Services, National Institutes of Health, U.S. National Library of Medicine. (2018). The reports of the Surgeon General: The 1964 report on smoking and health. Retrieved from <https://profiles.nlm.nih.gov/ps/retrieve/Narrative/NN/p-nid/60>
44. Higgins, S. T., & Petry, N. M. (1999). Contingency management: Incentives for sobriety. *Alcohol Research & Health, 23*(2), 122–127.
45. Higgins, S. T., Silverman, K., & Heil, S. H. (Eds.). (2008). *Contingency management in substance abuse treatment*. New York, NY: The Guilford Press.
46. Wright, T. E., Schuetter, R., Fombonne, E., Stephenson, J., & Haning, W. F., III. (2012). Implementation and evaluation of a harm-reduction model for clinical care of substance using pregnant women. *Harm Reduction Journal, 9*, 5. doi: 10.1186/1477-7517-9-5
47. Jones, H. E., Haug, N., Silverman, K., Stitzer, M., & Svikis, D. (2001). The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. *Drug and Alcohol Dependence, 61*(3), 297–306.
48. Hand, D. J., Ellis, J. D., Carr, M. M., Abatemarco, D. J., & Ledgerwood, D. M. (2017). Contingency management interventions for tobacco and other substance use disorders in pregnancy. *Psychology of Addictive Behaviors, 31*(8), 907–921. doi: 10.1037/adb0000291
49. Elk, R., Schmitz, J., Spiga, R., Rhoades, H., Andres, R., & Grabowski, J. (1995). Behavioral treatment of cocaine-dependent pregnant women and TB-exposed patients. *Addictive Behaviors, 20*(4), 533–542. doi: 10.1016/0306-4603(94)00076-B
50. Elk, R., Mangus, L., Rhoades, H., Andres, R., & Grabowski, J. (1998). Cessation of cocaine use during pregnancy: Effects of contingency management interventions on maintaining abstinence and complying with prenatal care. *Addictive Behaviors, 23*(1), 57–64. doi: 10.1016/S0306-4603(97)00020-8
51. Cahill, K., Hartmann-Boyce, J., & Perera, R. (2015). Incentives for smoking cessation. *Cochrane Database of Systematic Reviews, 5*, CD004307. doi: 10.1002/14651858.CD004307.pub5

52. Schuster, R. M., Hanly, A., Gilman, J., Budney, A., Vandrey, R., & Evins, A. E. (2016). A contingency management method for 30-days abstinence in non-treatment seeking young adult cannabis users. *Drug and Alcohol Dependence*, *167*, 199–206. doi: 10.1016/j.drugalcdep.2016.08.622
53. Ko, J. Y., Rockhill, K. M., Tong, V. T., Morrow, B., & Farr, S. L. (2017). Trends in postpartum depressive symptoms: 27 states, 2004, 2008, and 2012. *Morbidity and Mortality Weekly Report*, *66*, 153–158. doi: 10.15585/mmwr.mm6606a1
54. Ryan, S. A., Ammerman, S. D., & O'Connor, M. J. (2018). Marijuana use during pregnancy and breastfeeding: Implications for neonatal and childhood outcomes. *Pediatrics*, *142*, e20181889.
55. Kelley, S. J. (1998). Stress and coping behaviors of substance-abusing mothers. *Journal of Pediatric Nursing*, *3*(3), 103–110.
56. Hoye, J., Asok, A., Bernard, K., Roth, T. L., Rosen, J. B., & Dozier, M. (2013). *Intervening early to protect telomeres: Results of a randomized clinical trial*. Unpublished manuscript.
57. Koniak-Griffin, D., Anderson, N. L., Verzemnieks, I., & Brecht, M. L. (2000). A public health nursing early intervention program for adolescent mothers: Outcomes from pregnancy through 6 weeks postpartum. *Nursing Research*, *49*(3), 130–138.
58. Koniak-Griffin, D., Anderson, N. L., Brecht, M. L., Verzemnieks, I., Lesser, J., & Kim, S. (2002). Public health nursing care for adolescent mothers: Impact on infant health and selected maternal outcomes at 1 year postbirth. *Journal of Adolescent Health*, *30*(1), 44–54.
59. Williams, C. M., Asaolu, I., English, B., Jewell, T., Smith, K., & Robl, J. (2014). *Maternal and child health improvement by HANDS home visiting program in the bluegrass area development district*. Unpublished manuscript, Department of Obstetrics and Gynecology, University of Kentucky, Lexington, KY.
60. Olds, D. L., Kitzman, H. J., Cole, R. E., Hanks, C. A., Arcoleo, K. J., Anson, E. A., . . . Stevenson, A. J. (2010). Enduring effects of prenatal and infancy home visiting by nurses on maternal life course and government spending: Follow-up of a randomized trial among children at age 12 years. *Archives of Pediatrics & Adolescent Medicine*, *164*(5), 419–424. doi: 10.1001/archpediatrics.2010.49
61. Olds, D. L., Kitzman, H., Hanks, C., Cole, R., Anson, E., Sidora-Arcoleo, K., . . . Bondy, J. (2007). Effects of nurse home visiting on maternal and child functioning: Age-9 follow-up of a randomized trial. *Pediatrics*, *120*(4), e832–e845. doi: 10.1542/peds.2006-2111
62. Olds, D., Henderson, C. R., Jr., Cole, R., Eckenrode, J., Kitzman, H., Luckey, D., . . . Powers, J. (1998). Long-term effects of nurse home visitation on children's criminal and antisocial behavior: 15-year follow-up of a randomized controlled trial. *Journal of the American Medical Association*, *280*(14), 1238–1244.
63. Eckenrode, J., Campa, M., Luckey, D. W., Henderson, C. R., Jr., Cole, R., Kitzman, H., . . . Olds, D. (2010). Long-term effects of prenatal and infancy nurse home visitation on the life course of youths: 19-year follow-up of a randomized trial. *Archives of Pediatrics & Adolescent Medicine*, *164*(1), 9–15. doi: 10.1001/archpediatrics.2009.240
64. Kitzman, H., Olds, D. L., Cole, R., Hanks, C., Anson, E., Arcoleo, K., . . . Holmberg, J. (2010). Enduring effects of prenatal and infancy home visiting by nurses on children: Age 12 follow-up of a randomized trial. *Archives of Pediatrics & Adolescent Medicine*, *164*(5), 412–418. doi: 10.1001/archpediatrics.2010.76
65. Olds, D. L., Eckenrode, J., Henderson, C. R., Jr., Kitzman, H., Powers, J., Cole, R., . . . Luckey, D. (1997). Long-term effects of home visitation on maternal life course and child abuse and neglect. Fifteen-year follow-up of a randomized trial. *Journal of the American Medical Association*, *278*(8), 637–643.

66. Zielinski, D. S., Eckenrode, J., & Olds, D. L. (2009). Nurse home visitation and the prevention of child maltreatment: Impact on the timing of official reports. *Development and Psychopathology, 21*(2), 441–453. doi: 10.1017/S0954579409000248
67. Chazan-Cohen, R., Raikes, H., & Vogel, C. (2013). V. program subgroups: Patterns of impacts for home-based, center-based, and mixed-approach programs. *Monographs of the Society for Research in Child Development, 78*(1), 93–109. doi: 10.1111/j.1540-5834.2012.00704
68. Roberts, S. C. M., Mericle, A. A., Subbaraman, M. S., Thomas, S., Treffers, R. D., Delucchi, K. L., & Kerr, W. C. (2019). State policies targeting alcohol use during pregnancy and alcohol use among pregnant women 1985 – 2016: Evidence from the Behavioral Risk Factor Surveillance System. *Women's Health Issues, 29*(3), 213–221. doi: 10.1016/j.whi.2019.02.001
69. U.S. Department of Health and Human Services, Head Start Bureau. (2002). *Making a difference in the lives of infants and toddlers and their families: The impacts of Early Head Start: Volumes I-III, Final technical report, appendixes, and local contributions to understanding the programs and their impacts*. Retrieved from Office of Planning, Research, & Evaluation website: <https://www.acf.hhs.gov/opre/resource-library/search?sort=recent>
70. Kitzman, H., Olds, D. L., Sidora, K., Henderson, C. R., Jr., Hanks, C., Cole, R., . . . Glazner, J. (2000). Enduring effects of nurse home visitation on maternal life course: A 3-year follow-up of a randomized trial. *Journal of the American Medical Association, 283*(15), 1983–1989. doi:10.1001/jama.283.15.1983
71. Chang, H., Shaw, D. S., Shelleby, E. C., Dishion, T. J., & Wilson, M. N. (2017). The long-term effectiveness of the family check-up on peer preference: Parent-child interaction and child effortful control as sequential mediators. *Journal of Abnormal Child Psychology, 45*(4), 705–717. doi: 10.1007/s10802-016-0198-9
72. Bishop, D., Borkowski, L., Couillard, M., Allina, A., Baruch, S., & Wood, S. (2017). *Bridging the divide white paper: Pregnant women and substance use: Overview of research & policy in the United States* (Paper 5). Retrieved from The George Washington University, Jacobs Institute of Women's Health website: https://hsrc.himmelfarb.gwu.edu/sphhs_centers_jacobs/5
73. Stone, R. (2015). Pregnant women and substance use: Fear, stigma, and barriers to care. *Health & Justice, 3*, 2. doi: 10.1186/s40352-015-0015-5
74. Laixuthai, A., & Chaloupka, F. J. (1993). Youth alcohol use and public policy. *Contemporary Economic Policy, 11*(4), 70–81. doi: 10.1111/j.1465-7287.1993.tb00402
75. Coate, D., & Grossman, M. (1988). Effects of alcoholic beverage prices and legal drinking ages on youth alcohol use. *The Journal of Law and Economics, 31*(1), 145–171.
76. Grossman, M., Chaloupka, F. J., Saffer, H., & Laixuthai, A. (2010). Effects of alcohol price policy on youth: A summary of economic research. *Journal of Research on Adolescence, 4*(2), 347–364.
77. Hollingworth, W., Ebel, B. E., McCarty, C. A., Garrison, M. M., Christakis, D. A., & Rivara, F. P. (2006). Prevention of deaths from harmful drinking in the United States: The potential effects of tax increases and advertising bans on young drinkers. *Journal of Studies on Alcohol, 67*(2), 300–308.
78. Williams, J., Chaloupka, F. J., & Wechsler, H. (2005). Are there differential effects of price and policy on college students' drinking intensity? *Contemporary Economic Policy, 23*(1), 78–90. doi: 10.3386/w8702
79. Saffer, H., & Grossman, M. (1987). Beer taxes, the legal drinking age, and youth motor vehicle fatalities. *The Journal of Legal Studies, 16*(2), 351–374.

80. Ponicki, W. R., Gruenewald, P. J., & LaScala, E. A. (2007). Joint impacts of minimum legal drinking age and beer taxes on US youth traffic fatalities, 1975 to 2001. *Alcoholism: Clinical and Experimental Research*, 31(5), 804–813. doi: 10.1111/j.1530-0277.2007.00363
81. Young, D. J., & Bielinska-Kwapisz, A. (2006). Alcohol prices, consumption, and traffic fatalities. *Southern Economic Journal*, 72(3), 690–703. doi: 10.2307/20111841
82. Bormann, C. A., & Stone, M. H. (2001). The effects of eliminating alcohol in a college stadium: The Folsom Field beer ban. *Journal of American College Health*, 50(2), 81–88. doi: 10.1080/07448480109596011
83. Johannessen, K., Glider, P., Collins, C., Hueston, H., & DeJong, W. (2001). Preventing alcohol-related problems at the University of Arizona’s homecoming: An environmental management case study. *The American Journal of Drug and Alcohol Abuse*, 27(3), 587–597. doi: 10.1081/ADA-100104520
84. Toomey, T. L., Erickson, D. J., Patrek, W., Fletcher, L. A., & Wagenaar, A. C. (2005). Illegal alcohol sales and use of alcohol control policies at community festivals. *Public Health Reports*, 120(2), 165–173. doi: 10.1177/003335490512000210
85. Cavazos-Rehg, P. A., Krauss, M. J., Spitznagel, E. L., Chaloupka, F. J., Schootman, M., Gruzca, R. A., & Bierut, L. J. (2012). Associations between selected state laws and teenagers’ drinking and driving behaviors. *Alcoholism: Clinical and Experimental Research*, 36(9), 1647–1652. doi: 10.1111/j.1530-0277.2012.01764
86. U.S. Department of Transportation, National Highway Traffic Safety Administration. (2001). Evaluation of use and lose laws. Retrieved from <https://one.nhtsa.gov/people/injury/research/pub/alcohol-laws/eval-of-law/page1.html>
87. Fell, J. C., Fisher, D. A., Voas, R. B., Blackman, K., & Tippetts, A. S. (2009). The impact of underage drinking laws on alcohol-related fatal crashes of young drivers. *Alcoholism: Clinical and Experimental Research*, 33(7), 1208–1219. doi: 10.1111/j.1530-0277.2009.00945
88. Voas, R. B., Tippetts, A. S., & Fell, J. C. (2003). Assessing the effectiveness of minimum legal drinking age and zero tolerance laws in the United States. *Accident Analysis & Prevention*, 35(4), 579–587.
89. Smith, R. C., & Geller, E. S. (2009). Marketing and alcohol-related traffic fatalities: Impact of alcohol advertising targeting minors. *Journal of Safety Research*, 40(5), 359–364. doi: 10.1016/j.jsr.2009.08.001
90. Saffer, H., & Dave, D. (2010). Alcohol consumption and alcohol advertising bans. *Applied Economics*, 34(11), 1325–1334. doi: 10.1080/00036840110102743

Examples of Effective Prevention Programs

This chapter highlights six prevention programs designed to address and reduce substance misuse among pregnant and postpartum women. Each program uses one or more of the evidence-based practices described in Chapter 2. The Chapter 2 practices featured include:

- Screening, brief intervention, and referral to treatment (SBIRT)
- Integrated clinics for pregnant and parenting women
- Health communication campaigns to change behaviors
- Contingency management for reducing marijuana use
- Postpartum home visits by health professionals
- Policies to prevent and reduce marijuana use

While there may be programs that focus on the prevention of marijuana use among pregnant or postpartum women, there is limited research or data available on the effectiveness of any such program.

The best available data comes from programs that focus on preventing tobacco, alcohol, opioids, heroin, and other substance misuse among pregnant and postpartum women. Lessons from these successful



programs may be applied to programming for marijuana use prevention. For example, while the CDC's *Tips From Former Smokers*® (*Tips*®) campaign addresses tobacco use, its strategies focus on messaging that affect behaviors and, therefore, can be generalized to address marijuana use as well.

Choosing Programs

While there are additional effective programs that could have been featured in this chapter, the programs described below were considered to be well defined, promising, and representative of prevalent practice models, according to the technical panel of experts who provided input on this guide. These programs meet the evidence-based criteria and practices featured in Chapter 2. Each program has achieved positive outcomes for the prevention of substance misuse among pregnant or postpartum women.

Overview of Programs Featured

	Kaiser Permanente Early Start	Tips® Campaign	BABY & ME - Tobacco Free	University of New Mexico Milagro Program	Minimum Age of Purchase, Sale, and Server Laws	Advertising Restrictions
Evidence-Based Practice(s) Featured	SBIRT Integrated Clinics	Health Communication Campaign	Contingency Management	Integrated Clinics Postpartum Home Visits	Policies to Prevent and Reduce Marijuana Use	Policies to Prevent and Reduce Marijuana Use
Substance(s) Addressed	Alcohol Tobacco Illicit Drugs	Tobacco	Tobacco	Tobacco Alcohol Marijuana Opiates Methamphetamine Illicit Drugs	Alcohol	Alcohol
Focus on Pregnancy	✓	✓	✓	✓		
Focus on Postpartum Period			✓	✓		
Populations of Focus	Pregnant Women	General Public Women of Child-Bearing Age Pregnant Women	Pregnant Women Postpartum Women Qualifying Support Partner	Pregnant and Postpartum Women with Substance Use Disorders Family Members	Youth less than 21 years of age	Youth less than 21 years of age

Format of the Chapter

For each of the six programs featured within this chapter, uniform headings present information such as key features, implementation strategies, populations of focus, outcomes, and more.

Key Features

- The program's co-location in a prenatal clinic ensures universal screening and consistent early identification of substance misuse.
- Licensed Early Start specialists provide assessment, information, and early intervention.
- The program incorporates prenatal provider education, consultation, and training to support effective program operation.

Evidence-Based Practice

SBIRT; integrated clinics

Preventing Substance Misuse

Alcohol; tobacco; illicit drugs

Populations of Focus

Women served in Kaiser Permanente prenatal care settings who use substances. Kaiser Permanente is a large not-for-profit health plan that serves 12.3 million members across the United States.

Kaiser Permanente Early Start

<https://earlystart.kaiserpermanente.org>

Program Description

Kaiser Permanente's Early Start is a program to improve neonatal outcomes for babies of substance-using women who receive care at community-based outpatient obstetric clinics. The program integrates substance use prevention and treatment services with routine prenatal care and places Early Start specialists within the care team to provide counseling services on-site.

Pregnant women at risk for using alcohol, tobacco, and/or misusing other substances during pregnancy receive immediate assessment, intervention, and ongoing case management services with their routine prenatal visits. Referrals to SUD treatment and other community support programs are available. Most women see the Early Start specialist only once, though women who need additional support can receive follow-up visits.

Opportunities

The Early Start Program provides pregnant women with a range of benefits to help them have a healthy pregnancy and a healthy baby, including:

- Facilitating universal screening and early identification of pregnant women misusing substances
- Integrating SUD services into routine prenatal care
- Providing specialist counseling services on-site at the primary care clinic

Implementation Strategies


Staffing: In large clinic settings, staffing consists of one full-time licensed Early Start specialist for every 1,800 births. In smaller community settings, the amount of staffing time needed could be prorated according to the number of annual births occurring at several clinics.

Cost: Kaiser's Early Start implementation costs in northern California were \$670,600 annually (including costs for 27.4 full-time equivalent Early Start specialists). A cost-benefit analysis showed a net cost benefit averaging \$5,946,741 per year, indicating that the benefits derived from implementing the program far outweighed the costs of implementing it.¹



Early Start

Outcomes




Of women who participated in the program, **69%** did not engage in any illicit drug use during pregnancy or through delivery.^{2,3}



Mothers who participated in the program also experienced:

- Fewer preterm deliveries^{4,5}
- Fewer stillborn births^{4,5}
- Fewer placental abruptions^{4,5}
- Lower cost of maternal care, as compared to women with SUDs who did not participate in the program¹



Babies born to mothers who participated in the program experienced:

- Lower rates of assisted ventilation^{4,5}
- Healthier birth weights^{4,5}

Key Features⁶

- Media placement for this campaign reaches three-quarters of U.S. adults.⁶
- *Tips* advertisements have appeared on television in all U.S. media markets through commercial advertising time on cable television networks.⁶
- The campaign had a ubiquitous national buy and a local “buy up” strategy in which the campaign was broadcast through smaller local television channels in media markets with a high prevalence of cigarette smoking.⁶

Evidence-Based Practice

Health communication campaign

Preventing Substance Misuse

Tobacco

Populations of Focus

The general public, women of child-bearing age, and pregnant women.

Secondary audiences include family members, healthcare providers, and faith communities.

It is important to note that the evidence on health effects of marijuana use is still emerging. A campaign centered on health effects should be careful to focus on those aspects of health risks of marijuana that are well-established (e.g., low birth weight, preterm birth, transfer of THC to baby in breast milk, cognitive effects on offspring).

Tips From Former Smokers[®] (*Tips*[®]) Campaign

<https://www.cdc.gov/tobacco/campaign/tips/index.html>

Program Description

The Centers for Disease Control and Prevention (CDC) launched the *Tips From Former Smokers*[®] (*Tips*[®]) campaign in March 2012. The *Tips* campaign features profiles of real people who are living with the serious long-term health effects of smoking and exposure to secondhand smoke. Over the course of this campaign, *Tips* has featured compelling stories from former smokers about their smoking-related diseases and disabilities, and the toll these conditions have had on their lives.

Tips advertisements focus on the health issues that are caused by, associated with, or made worse by smoking or secondhand smoke exposure. One of these issues is preterm birth.

Key messages in the *Tips* campaign include:

- Smoking causes immediate damage to your body, which can lead to long-term serious health problems.
- For every person who dies because of smoking, at least 30 people live with a serious smoking-related illness.
- Now is the time to quit smoking

Opportunities

Through the *Tips* campaign website, the CDC provides free resources for those seeking to quit or help others quit smoking. Examples of these materials include:

- Social media images
- FAQs
- Expert talking points
- A pocket card for talking with smokers who want to quit

These materials are customized for use by specific audiences, including faith-based organizations, healthcare providers, organizations serving military members and veterans, and organizations serving residents in public housing.

**TIPS FROM
FORMER
SMOKERS**

The *Tips* campaign website also offers clinical tools for providers to help them counsel individuals on how to quit smoking (<https://www.cdc.gov/tobacco/campaign/tips/partners/health/index.html>).

Implementation Strategies

The *Tips* campaign is a national initiative that is well-funded and designed by an advertising firm. Essential lessons for implementation of smaller-scale communication campaigns include:

Planning: Consider key messages, define target audiences, and focus on reach and channels for getting the message out.

Stakeholder engagement: Engage key stakeholders—including healthcare providers, opinion leaders, and other influential people—in getting the message out.

Graphic and personal portrayals of negative health consequences: Demonstrate the real harms that are associated with substance use in ways that are likely to elicit an emotional response.

Outcomes



It is estimated that **80% of US cigarette smokers** saw at least one *Tips* message in 2012. Audiences averaged 23 views over a 12-week period.⁶

As a result of the *Tips* campaign:⁶⁻¹⁰

Non-smokers reported increased conversations with family or friends about the dangers of smoking.

Non-smokers reported greater knowledge of smoking-related diseases.

Smokers who saw ads reported greater intentions to quit within 30 days and 6 months.

Smokers who saw the ads multiple times reported even greater intentions to quit.



Exposure to the ads was associated with increased smoking cessation among pregnant women.¹¹

1.64 million smokers made a quit attempt.

100,000 smokers quit for good.

Approximately 17,000 premature deaths from smoking were averted.

179,000 years of healthy life were gained.



Key Features

- Women, and family members who live with the pregnant woman, are asked to attend four prenatal sessions where they receive information, resources, and other supports to help them quit smoking.
- After approximately two sessions, women and/or family members are tested for tobacco use using a carbon monoxide (CO) monitor.
- Those who are tobacco-free are rewarded with vouchers for diaper and baby wipe purchases.
- After childbirth, women can return monthly to the program to continue CO testing. Women receive diaper and baby wipe vouchers for each month they remain tobacco-free.

Evidence-Based Practice

Contingency management

Preventing Substance Misuse

Tobacco

Populations of Focus

Pregnant women who use tobacco or who recently quit. In some programs, qualifying support partners or family members may also enroll. BABY & ME – Tobacco Free programs are available in more than 20 states.

BABY & ME – Tobacco Free Program™

<http://babyandmetobaccofree.org>

Program Description

The BABY & ME – Tobacco Free Program™ is an evidence-based smoking cessation program created to reduce the impact of tobacco use on pregnant and postpartum women and their children. The program's primary goal is to reduce infant mortality and morbidity by helping women stop or reduce smoking while pregnant and after childbirth. The program also helps family members who live with pregnant and postpartum women avoid tobacco use.

During pregnancy, the program engages women and family members in prenatal information sessions. Those who stop smoking while attending the sessions are provided with incentives, such as diaper vouchers. Women are encouraged to return to the program after their child is born. Women who continue to abstain from tobacco receive incentives up to 12 months postpartum.

Opportunities

The BABY & ME – Tobacco Free Program helps pregnant and postpartum women, as well as their families, by:

- Ensuring program facilitators are trained in motivational interviewing techniques and are focused on the stages of change
- Developing individualized tobacco cessation strategies in partnership with each woman, tailored to her situation
- Incentivizing regular program participation and progress through vouchers
- Providing ongoing monitoring of smoking behaviors during both pregnancy and the postpartum period




Implementation Strategies

Staffing: Agencies, stakeholders, and facilitators must complete a one-day training. During the training, participants are given all information and materials necessary to implement and enroll women into the program. Additional technical assistance is available through the national BABY & ME – Tobacco Free program office.

Funding sources: Some states and health insurance providers reimburse sites offering the program. Additional funding may be identified and available through partnerships with departments of public health, community-based health centers, physician offices, and other health and human service agencies.

Outcomes

Women who participate in the BABY & ME – Tobacco Free Program have better maternal and infant outcomes.¹²⁻¹⁴



Key Features

- Treatment plans are customized to fit the needs of the expectant mother and include prevention strategies and supports.
- Treatment teams made up of relevant healthcare professionals holistically address each woman's needs.
- Care is integrated with UNM hospitals and allows the provider team to follow women and their newborns during inpatient hospital stays.
- Medication-assisted treatment (MAT) is available for women with an opioid use disorder (OUD), with all maternity care providers prescribing buprenorphine.

Evidence-Based Practices

Integrated clinics; postpartum home visits

Preventing Substance Misuse

Tobacco; alcohol; marijuana; opioids; methamphetamine; other illicit drugs

Populations of Focus

Pregnant women and their families with SUDs throughout New Mexico and surrounding areas, with most participants residing in the Albuquerque metropolitan area.

More than 90 percent of the women in the program have an OUD and are on MAT. Many, however, have polysubstance misuse, most commonly reporting methamphetamine and marijuana as secondary substances.

University of New Mexico Milagro Program

<https://hsc.unm.edu/health/patient-care/behavioral-health/addiction-recovery/prenatal-program.html>

Program Description

The University of New Mexico (UNM) Milagro Program is for pregnant women with an alcohol and substance use history or who are currently using substances. The program seeks to prevent and treat substance misuse during and after pregnancy. Women involved in the program receive their prenatal care from UNM Health System providers in the system's family medicine clinics. Additionally, a team of providers, including counseling, case management, and other professionals, works together to ensure the well-being of the mother. The team works with the pregnant woman and her family before and after the baby is born.

The program started in 1989 and is one of the oldest integrated prenatal programs that addresses SUDs. The program screens for many substances, including tobacco, alcohol, marijuana, opioids, and other drugs. Due to the program's integrated approach to health care, it can address the needs of women through inpatient stays, outpatient clinic visits, in the community, and even at home. Services include high-risk prenatal care, SUD treatment and counseling, case management, parenting classes, domestic violence support groups, trauma counseling, anger management counseling, and relapse prevention planning.

Opportunities

Care is provided through an integrated network of inpatient and outpatient healthcare and social service providers. Integrated provider teams develop trauma-informed care and treatment plans to address prenatal care, childbirth and postpartum care, substance use prevention and treatment, and care for the baby. Individualized treatment plans may include:

- In-hospital care for stabilization with methadone or buprenorphine
- Services offered in English and Spanish
- Treatment for spouses and partners



- Coordination with affiliated residential facility, an alternative to incarceration
- Collaboration and postpartum transition of care to a program for the entire family which provides trauma-informed care including case management; newborn, pediatric, and developmental care for babies; and ongoing substance use care including MAT for parents for up to three years after delivery

Implementation Strategies

Staffing: Integrated provider teams include case managers, care coordinators, community health workers, nurses, substance misuse counselors, family medicine residents, and staff physicians.

Costs: Much of the program’s cost can be covered by health insurance. In some cases, state policies dictate whether case management services are reimbursed.

Funding sources: The Milagro program was originally funded by a SAMHSA grant. The program has sustained operations through a combination of state and local funding, combined with medical billing.

Outcomes

The Milagro program offers impressive benefits to the women it serves:^{16,17}



of pregnant women prescribed buprenorphine continued on the medication until delivery.



of women who start MAT for OUDs have negative urine drug screenings, meaning they are no longer engaging in opioid use.



of the women will be breastfeeding their infants upon hospital discharge following delivery.



of the women will be breastfeeding their infants at 2 months after delivery.

Key Features

- State-specific policies have been designed to reduce underage drinking by limiting minors' access to alcohol.
- Policies can regulate the minimum age of alcohol purchase, seller, and server laws.
- Policies also can control pro-alcohol messaging through alcohol advertising restrictions.

Evidence-Based Practice

Policies to prevent and reduce marijuana use

Preventing Substance Misuse

Alcohol

Populations of Focus

Youth less than 21 years of age

Minimum Age of Purchase, Sale, and Server Laws

<https://alcoholpolicy.niaaa.nih.gov>

Program Description

Evidence shows that policies limiting minors' access to alcohol can reduce alcohol initiation and consumption among adolescents, both of which have been linked to problem drinking in adulthood.²⁴ Similarly, early initiation of marijuana use is linked to marijuana use during pregnancy.¹⁹⁻²³

Minimum age of alcohol purchase, seller, and server laws are a suite of alcohol control policies that stipulate the minimum age for alcohol transactions.

- 1. Minimum age of purchase laws** prohibit minors from buying or attempting to buy alcoholic beverages.
- 2. Minimum age of seller laws** specify a minimum age for employees who sell alcoholic beverages in off-premises establishments (e.g., liquor, grocery, and convenience stores).
- 3. Minimum age of server laws** specify a minimum age for employees who serve or dispense alcoholic beverages in on-premises establishments (e.g., bars and restaurants).

Legal parameters of these policies—including age restrictions, compliance checks, vendor/retailer sanctions, and more—vary by state. State-level information on key components of [purchase](#), [seller](#), and [server laws](#), as well as the use of [false identification](#), can be found at the Alcohol Policy Information System website: <https://alcoholpolicy.niaaa.nih.gov>.

Opportunities

Laws regulating the minimum age of alcohol purchasers, sellers, and servers are designed to change drinking behavior among young people, many of whom are women of child-bearing age. The same would be true of similar policies limiting minors' access to marijuana (in states where recreational marijuana use has been legalized).

Youth marijuana use prevention champions and stakeholders can collaborate with community leaders to pinpoint ways to strengthen existing laws in states where recreational marijuana use has been legalized. For example, if the state does not already do so, champions and stakeholders can consider enhancing current efforts to prevent minors from using false identification (ID) to purchase marijuana by:

- Prohibiting the production, sale, distribution, possession, and use of false IDs for attempted marijuana purchase
- Implementing universal ID checks of all marijuana customers
- Requiring two or more different ID cards at point of purchase
- Issuing driver licenses and state ID cards that can be electronically scanned²⁴
- Allowing retailers to confiscate apparently false IDs for law enforcement inspection²⁵
- Using holographs and colors to make the manufacture of false IDs more difficult²⁶

Implementation Strategies

Collaboration: Foster collaboration between prevention champions/stakeholders and community leaders and their staff to help draft revisions to, and shepherd, new legislation.

State-level support: Utilize media advocacy strategies to increase awareness and garner state-level support for policy revisions.

Enhanced enforcement activities:

Enhance enforcement activities (through collaboration between stakeholders and community leaders) related to minimum age of transaction laws, such as compliance checks or compliance surveys and responsible server training.

Informational opportunities: Provide informational opportunities (other than direct mail) to retailers and the general public about policy changes, compliance requirements, enforcement methods, and penalties as needed to enhance deterrence effects.²⁷

Additional guidance: Learn more about implementation strategies for underage alcohol control policies, and consider how they could be translated into underage marijuana prevention policies, through the following resources:

- [Report to Congress on the Prevention and Reduction of Underage Drinking](#)
- [State Performance and Best Practices for the Prevention and Reduction of Underage Drinking](#)
- [Effectiveness of Sanctions and Law Enforcement Practices Targeted at Underage Drinking Not Involving Operation of a Motor Vehicle](#)
- [Policies to Reduce Commercial Access to Alcohol](#)
- [Regulatory Strategies for Preventing Youth Access to Alcohol: Best Practices](#)

Outcomes

Underage drinking policies lower drinking rates among underage youth:

- Compared to geographic areas with fewer underage drinking policies, areas with four or more underage laws (e.g., laws requiring a minimum age for servers and sellers, fake ID restrictions, laws on attempts to purchase or consume, laws requiring the posting of warning signs in alcohol outlets) have:²⁸
 - Lower alcohol use rates
 - Lower rates of drinking in the past 30 days
 - Lower binge-drinking rates
- States with stricter laws regarding the use of false IDs to purchase alcohol have:²⁹
 - Lower rates of alcohol-related traffic fatalities involving underage drinkers
- States with laws establishing 21 as the minimum age to sell alcohol have:²⁸
 - Lower alcohol use
 - Lower binge-drinking rates

Key Features

- State-level advertising regulations have been designed to reduce underage drinking through provisions that prohibit false or misleading alcohol advertising, advertising that targets underage youth, and advertising where youth are likely to be present, including on college campuses.³⁰
- Other kinds of restrictions (e.g., local ordinance or voluntarily implemented business, event, or organizational policies) have been designed to minimize youth exposure to alcohol promotion and advertising in public venues, such as on public transportation and at community events.³¹

Evidence-Based Practice

Policies to prevent and reduce marijuana use

Preventing Substance Misuse

Alcohol

Populations of Focus

Youth less than 21 years of age

Advertising Restrictions

http://www.camy.org/docs/research-to-practice/promotion/legal-resources/state-ad-laws/CAMY_State_Alcohol_Ads_Report_2012.pdf

Program Description

Evidence shows that policies restricting exposure to pro-alcohol advertising can reduce alcohol initiation and consumption among adolescents, both of which have been linked to problem drinking in adulthood.¹⁸ Similarly, early initiation of marijuana use is linked to marijuana use during pregnancy.¹⁹⁻²³

Advertising restrictions include any policies that limit advertising of alcoholic beverages, particularly advertisements that expose young people to pro-alcohol messages. Such policies can include regulations on electronic media (e.g., radio, television, internet), print media (e.g., magazines and newspapers), outdoor billboards, and signs.

Opportunities

Policy restrictions on alcohol advertising to minors can be applied to prevention efforts around marijuana use in women of child-bearing age, many of whom are minors and would be included in the primary audience of any such efforts.

Several lessons from alcohol advertising policy restrictions could benefit similar restrictions around marijuana (in states where its recreational use has been legalized) including:

- Establishing a distance threshold, including all types of marijuana advertising, and displaying the international “child” symbol on any billboard in the exclusionary zone
- Prohibiting advertising in student publications of all college campuses located in the state that have a substantial readership less than 21 years old, providing exceptions to protect advertisers’ ability to reach those of legal age
- Considering a multifaceted approach by combining advertising restrictions with other underage marijuana use prevention efforts or interventions to maximize overall effectiveness (in terms of alcohol use, examples of such interventions include keg registration, mandatory responsible beverage service training, and enforcement of bar capacity regulations)³²

Implementation Strategies

Lawmaking body: Most states use their Alcoholic Beverage Control (ABC) agency to administer advertising regulations, since alcohol distributors and retailers must obtain licenses from this agency to do business in a state. The ABC agency has the authority to enact regulations, investigate infractions, and impose sanctions as needed.³⁰

Experienced team members: Individuals or organizations with expertise in supporting the adoption, implementation, and enforcement of new regulations (or modifications to existing regulations) are essential to implementing alcohol advertising restrictions.


Prevention champions and stakeholders:

Stakeholders committed to preventing marijuana use among minors (including pregnant women) are key to mobilizing and building support for this type of policy within a community. Stakeholders can include law enforcement; religious, educational, or parent groups; town councils; and local advertising or marketing firms.

Additional guidance: Learn more about implementation strategies for underage alcohol advertising regulations, and consider how they could be translated into underage marijuana advertising regulations, through the following resources:

- [Alcohol Marketing and Advertising: A Report to Congress](#)
- [Center on Alcohol Marketing and Youth](#)
- [Out of Home Advertising Association of America: Code of Industry Principles](#)

Outcomes



Underage alcohol advertising regulations lower drinking rates among underage youth. Both partial bans and complete bans on alcohol advertising have been associated with reduced alcohol consumption in 20 countries.^{33,34}



States with laws prohibiting alcohol advertising targeting minors have fewer youth alcohol-related, single-vehicle, driver traffic fatalities compared to states without this regulation.³⁵



Alcohol advertising regulations have been associated with:³⁶

- Lower rates of adolescent alcohol consumption
- Reduced frequency of adolescent alcohol consumption
- Older age of first alcohol use



Youth who lived in markets with less alcohol advertising were found to:³⁷

- Drink less
- Increase their drinking more modestly until their early 20s

Reference List

1. Goler, N. C., Armstrong, M. A., Osejo, V. M., Hung, Y. Y., Haimowitz, M., & Caughey, A. B. (2012). Early Start: A cost-beneficial perinatal substance abuse program. *Obstetrics and Gynecology, 119*(1), 102–110. doi: 10.1097/AOG.0b013e31823d427d
2. Lieberman, L., Taillac, C., & Goler, N. (2005). Vision, research, innovation and influence: Early Start's 15-year journey from pilot project to regional program. *The Permanente Journal, 9*(1), 62–64.
3. Armstrong, M. A., Lieberman, L., Carpenter, D. M., Gonzales, V. M., Usatin, M. S., Newman, L., & Escobar, G. J. (2001). Early Start: An obstetric clinic-based, perinatal substance abuse intervention program. *Quality Management in Health Care, 9*(2), 6–15.
4. Goler, N. C., Armstrong, M. A., Taillac, C. J., & Osejo, V. M. (2008). Substance abuse treatment linked with prenatal visits improves perinatal outcomes: A new standard. *Journal of Perinatology, 28*(9), 597–603. doi: 10.1038/jp.2008.70
5. Armstrong, M. A., Gonzales, O. V., Lieberman, L., Carpenter, D. M., Pantoja, P. M., & Escobar, G. J. (2003). Perinatal substance abuse intervention in obstetric clinics decreases adverse neonatal outcomes. *Journal of Perinatology, 23*(1), 3–9.
6. McAfee, T., Davis, K. C., Alexander, R. L., Jr., Pechacek, T. F., & Bunnell, R. (2013). Effect of the first federally funded US antismoking national media campaign. *The Lancet, 382*(9909), 2003–2011. doi: 10.1016/S0140-6736(13)61686-4
7. Davis, K. C., Patel, D., Shafer, P., Duke, J., Glover-Kudon, R., Ridgeway, W., & Cox, S. (2018). Association between media doses of the Tips From Former Smokers Campaign and cessation behaviors and intentions to quit among cigarette smokers, 2012–2015. *Health Education & Behavior, 45*(1), 52–60. doi: 10.1177/1090198117709316
8. McAfee, T., Davis, K. C., Shafer, P., Patel, D., Alexander, R., & Bunnell, R. (2017). Increasing the dose of television advertising in a national antismoking media campaign: Results from a randomised field trial. *Tobacco Control, 26*(1), 19–28. doi: 10.1136/tobaccocontrol-2015-052517
9. Davis, K. C., Duke, J., Shafer, P., Patel, D., Rodes, R., & Beistle, D. (2017). Perceived effectiveness of antismoking ads and association with quit attempts among smokers: Evidence from the Tips From Former Smokers Campaign. *Health Communication, 32*(8), 931–938. doi: 10.1080/10410236.2016.1196413
10. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. (2019). Tips From Former Smokers. Retrieved from <https://www.cdc.gov/tobacco/campaign/tips/index.html>
11. England, L., Tong, V. T., Rockhill, K., Hsia, J., McAfee, T., Patel, D., . . . Davis, K. C. (2017). Evaluation of a federally funded mass media campaign and smoking cessation in pregnant women: A population-based study in three states. *BMJ Open, 7*(12), e016826. doi: 10.1136/bmjopen-2017-016826
12. Gadowski, A., Adams, L., Tallman, N., Krupa, N., & Jenkins, P. (2011). Effectiveness of a combined prenatal and postpartum smoking cessation program. *Maternal and Child Health Journal, 15*(2), 188–197. doi: 10.1007/s10995-010-0568-9
13. Zhang, X., Devasia, R., Czarnecki, G., Frechette, J., Russell, S., & Behringer, B. (2017). Effects of incentive-based smoking cessation program for pregnant women on birth outcomes. *Maternal and Child Health Journal, 21*(4), 745–751. doi: 10.1007/s10995-016-2166-y

14. Baby and Me Tobacco Free. (2019). Homepage. Retrieved from <http://babyandmetobaccofree.org>
15. Baby and Me Tobacco Free. (2019). Proven results. Retrieved from <http://babyandmetobaccofree.org/proven-results>
16. Kropp, F., Winhusen, T., Lewis, D., Hague, D., & Somoza, E. (2010). Increasing prenatal care and healthy behaviors in pregnant substance users. *Journal of Psychoactive Drugs, 42*(1), 73–81. doi: 10.1080/02791072.2010.10399787
17. Yonke, N., Maston, R., Weitzen, S., & Leeman, L. (2019). Breastfeeding intention compared with breastfeeding postpartum among women receiving medication-assisted treatment. *Journal of Human Lactation, 35*(1), 71–79. doi: 10.1177/0890334418769637
18. Hayatbakhsh, M. R., Najman, J. M., Bor, W., O’Callaghan, M. J., & Williams, G. M. (2009). Multiple risk factor model predicting cannabis use and use disorders: A longitudinal study. *The American Journal of Drug and Alcohol Abuse, 35*(6), 399–407. doi: 10.3109/00952990903353415
19. Passey, M. E., Sanson-Fisher, R. W., D’Este, C. A., & Stirling, J. M. (2014). Tobacco, alcohol and cannabis use during pregnancy: Clustering of risks. *Drug and Alcohol Dependence, 134*, 44–50. doi: 10.1016/j.drugalcdep.2013.09.008
20. Beatty, J. R., Svikis, D. S., & Ondersma, S. J. (2012). Prevalence and perceived financial costs of marijuana versus tobacco use among urban low-income pregnant women. *Addiction Research and Theory, 3*(4), doi: 10.4172/2155-6105.1000135
21. Moore, D. G., Turner, J. D., Parrott, A. C., Goodwin, J. E., Fulton, S. E., Min, M. O., . . . Singer, L. T. (2010). During pregnancy, recreational drug-using women stop taking ecstasy (3, 4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: Initial findings from the development and infancy study. *Journal of Psychopharmacology, 24*(9), 1403–1410. doi: 10.1177/0269881109348165
22. Mark, K., Gryczynski, J., Axenfeld, E., Schwartz, R. P., & Terplan, M. (2017). Pregnant women’s current and intended cannabis use in relation to their views toward legalization and knowledge of potential harm. *Journal of Addiction Medicine, 11*(3), 211–216. doi: 10.1097/ADM.0000000000000299
23. Hasin, D. S. (2018). US epidemiology of cannabis use and associated problems. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 43*(1), 195–212. doi: 10.1038/npp.2017.198
24. U.S. Department of Transportation, National Highway Traffic Safety Administration. (2001). Community how to guide on...public policy. Retrieved from http://www.nhtsa.gov/people/injury/alcohol/Community%20Guides%20HTML/Book6_PublicPolicy.html#App5
25. Pacific Institute for Research and Evaluation. (2011). *Regulatory strategies for prevention youth access to alcohol: Best practices*. Washington, DC: U.S. Department of Justice, Office of Juvenile Justice and Delinquency Prevention.
26. Wagenaar, A. C., Lenk, K. M., & Toomey, T. L. (2005). Policies to reduce underage drinking. In M. Galanter, C. Lowman, G. M. Boyd, V. B. Faden, E. Witt, & D. Lagressa (Eds.), *Recent Developments in Alcoholism* (pp. 275–297). Boston, MA: Springer.
27. Wolff, L. S., El Ayadi, A. M., Lyons, N. J., Herr- Zaya, K., Noll, D., Perfas, F., & Rots, G. (2011). Improving the alcohol retail environment to reduce youth access: A randomized community trial of a best practices toolkit intervention. *Journal of Community Health, 36*(3), 357–366. doi: 10.1007/s10900-010-9316-8

28. Wechsler, H., Lee, J. E., Nelson, T. F., & Kuo, M. (2002). Underage college students' drinking behavior, access to alcohol, and the influence of deterrence policies: Findings from the Harvard School of Public Health college alcohol study. *Journal of American College Health, 50*(5), 223–236. doi: 10.1080/07448480209595714
29. Fell, J. C., Fisher, D. A., Voas, R. B., Blackman, K., & Tippetts, A. S. (2008). The relationship of underage drinking laws to reductions in drinking drivers in fatal crashes in the United States. *Accident Analysis & Prevention, 40*(4), 1430–1440. doi: 10.1016/j.aap.2008.03.006
30. Center on Alcohol Marketing and Youth. (2012). *State laws to reduce the impact of alcohol marketing on youth: Current status and model policies*. Retrieved from http://www.camyo.org/action/LegalResources/State%20Ad%20Laws/CAMY_State_Alcohol_Ads_Report_2012.pdf
31. Sharp, W. (1992). *Mad at the ads: A citizen's guide to challenging alcohol advertising practices*. Washington, DC: Center for Science in the Public Interest.
32. Weitzman, E. R., Nelson, T. F., Lee, H., & Wechsler, H. (2004). Reducing drinking and related harms in college: Evaluation of the “A Matter of Degree” program. *American Journal of Preventive Medicine, 27*(3), 187–196. doi: 10.1016/j.amepre.2004.06.008
33. Saffer, H., & Dave, D. (2002). Alcohol consumption and alcohol advertising bans. *Applied Economics, 34*(11), 1325–1334. doi: 10.1080/00036840110102743
34. Saffer, H., & Dave, D. (2006). Alcohol advertising and alcohol consumption by adolescents. *Health Economics, 15*(6), 617–637. doi: 10.1002/hec.1091
35. Smith, R. C., & Geller, E. S. (2009). Marketing and alcohol-related traffic fatalities: Impact of alcohol advertising targeting minors. *Journal of Safety Research, 40*(5), 359–364. doi: 10.1016/j.jsr.2009.08.001
36. Paschall, M. J., Grube, J. W., & Kypri, K. (2009). Alcohol control policies and alcohol consumption by youth: A multi-national study. *Addiction, 104*(11), 1849–1855. doi: 10.1111/j.1360-0443.2009.02698
37. Snyder, L. B., Milici, F. F., Slater, M., Sun, H., & Strizhakova, Y. (2006). Effects of alcohol advertising exposure on drinking among youth. *Archives of Pediatrics & Adolescent Medicine, 160*(1), 18–24. doi: 10.1001/archpedi.160.1.18

Implementing Evidence-Based Substance Use Prevention Practices for Pregnant and Postpartum Women

Introduction

Prevention programs are more likely to be successful if organizations implement them thoughtfully. One comprehensive guide that can help organizations plan, implement, and evaluate prevention programs and practices—including those focused on preventing marijuana use among pregnant and postpartum women—is SAMHSA’s Strategic Prevention Framework (SPF).

SAMHSA developed the SPF to offer prevention planners a comprehensive approach to understanding and addressing the substance misuse and related behavioral health problems facing their states and communities. Visit SAMHSA’s website to learn more about the SPF (<https://www.samhsa.gov/sites/default/files/20190620-samhsa-strategic-prevention-framework-guide.pdf>).

Another helpful model for implementation is Getting to Outcomes® (GTO).¹ The 10-step GTO approach leads to increased capacity for prevention programs and better performance. This approach has been the centerpiece of a number of federal prevention resources.¹⁻³



Getting to Outcomes Model

Steps 1–6 of the GTO model focus on planning for implementation. Steps 7–10 focus on evaluation and quality improvement of prevention efforts. The model is meant to create a feedback loop whereby lessons learned from implementing prevention practices can inform future prevention initiatives.



Key Considerations for Implementing Prevention Practices and Programs

To maximize the impact of your intervention when implementing prevention programs, it is important to not only select the right program or practice, but also:

1. Maintain that program's core elements, and
2. Balance core elements with program adaptation so that it meets the needs of the people you serve and your capacity to implement.

Maintaining Core Program Elements

Once a program or practice is selected for implementation, planners need to identify which components of the intervention they will incorporate. Core intervention elements are the key ingredients to achieving good outcomes. Understanding and adhering to the principles underlying each core element may allow for flexibility in form without sacrificing the function associated with the element.

Knowing the core program elements may allow for more efficient and cost-effective implementation and lead to decisions about what can be adapted to suit local conditions. Core program elements may be best defined after several attempted applications of a program or practice, not just the original one.

Adapting the Program

Remaining faithful to the original design of an evidence-based program or practice, while addressing the unique needs and characteristics of the target audience, requires balancing the maintenance of core elements with adaptation. When planners change a program, they risk compromising outcomes. However, implementing a program that requires some adaptation may be more efficient and cost-effective than designing a program from scratch.

Some guidelines organizations can consider when balancing fidelity and adaptation include:

- Retaining core elements
- Building capacity before changing the program
- Adding rather than subtracting elements (adapting with care)
- Getting help from developers or other experts (if adapting)



Facilitating Factors of Implementation

The goal of implementation is to have practitioners base their interactions with women who are pregnant or postpartum on research findings around evidence-based practices and programs. Facilitating factors help accomplish this task and include the following.⁴



Ongoing Consultation and Coaching

Most of the skills practitioners need can be introduced in training, but really are learned on the job with the help of a consultant or coach. Training and coaching are the principal ways in which behavior change is brought about for selected staff in the beginning stages and throughout the process of implementing evidence-based practices and programs.



Pre-Service and In-Service Training

Trainings are efficient ways to impart knowledge of background information, theory, philosophy, and values. They also help to introduce the components and rationales of key practices and provide opportunities to practice new skills and receive feedback in a safe environment.



Facilitative Administrative Support

Facilitative administrative support provides leadership and makes use of a range of data inputs to inform decision making, support overall processes, and keep staff organized and focused on the desired outcomes.



Staff Selection

Beyond academic qualifications or experience factors, certain practitioner characteristics are difficult to teach in training sessions and are therefore a crucial part of the selection criteria. The staff selection process also can represent an intersection with larger system variables.



Staff and Program Evaluation

Staff evaluation is designed to assess the use and outcomes of the skills that are reflected in the staff selection criteria, taught in training, and reinforced and expanded in consultation and coaching processes. Assessments of practitioner performance and measures of fidelity also provide useful feedback to managers and implementers regarding the progress of implementation efforts and the usefulness of training and coaching.



System Interventions

System interventions are strategies that work with external systems to ensure availability of the financial, organizational, and human resources required to support the work of practitioners.



Challenges to Implementing Marijuana Use Prevention Programs Among Pregnant and Postpartum Women

Implementing programs to prevent marijuana use among pregnant and postpartum women can be challenging. Despite the possible benefits of such programs, barriers to their implementation exist that must be addressed. Primary barriers include discrimination and stigma that keep women from disclosing their substance use; lack of clinician time and training; and evolving changes in local, state, or federal policies around the legality and use of marijuana.⁵⁻⁷

Key to overcoming these challenges is informing stakeholders about the potential adverse health consequences of marijuana use for the pregnant woman, fetus, and postpartum mother and child. It is important to communicate the availability of effective prevention models to reduce such adverse health consequences. Information should be shared with expectant mothers and their families, health system administrators and practitioners, and other popular opinion leaders.

What follows are some of the primary challenges most commonly faced by community leaders who seek to implement prevention programs focused on marijuana use by pregnant and postpartum women. For each challenge, there are practical actions recommended.



Challenge

Public Misperception About the Safety of Marijuana Use

Actions

- Provide scientific and accurate information.
- Position information in strategic places where women will see it.
- Use technology and social media.

There is widespread public misperception about marijuana use and its adverse health effects on the body and brain.^{8,9} Pregnant and postpartum women may read inaccurate information about marijuana use, potentially believing that it is a “natural” or “safe” cure for pregnancy symptoms such as nausea and anxiety.¹⁰

It is important to expose pregnant and postpartum women to accurate information about the effects of marijuana use. Efforts to inform women about marijuana use should use or borrow from the largely successful efforts to inform women about the effects of tobacco use and alcohol consumption on maternal health, fetal health, and child development. Messages should be clear, direct, and simple, such as those in the *Tips From Former Smokers*[®] campaign (see Chapter 3 for more information).

Targeted placement of informational materials in doctors’ offices, health centers, salons, and baby supply stores can underscore key messages. Consider where pregnant and postpartum women, as well as their families and friends, will be exposed to messaging, and target prevention efforts accordingly. Find the right prevention vehicles for disseminating information. These could include social media, text messaging, or educational apps for electronic devices.





Challenge

Reluctance Among Pregnant Women to Admit to Marijuana Use

Actions

- Educate staff around how to discuss marijuana use in a non-judgmental manner.
- Train staff on motivational interviewing (see Chapter 2).¹¹
- Educate staff and health care system leadership regarding confidentiality issues such as the Health Insurance Portability and Accountability Act (HIPAA) and 42 CFR Part 2 regulations.*

The laws and regulations of almost all local, state, and federal jurisdictions contain language relating to marijuana use. In many communities, enforcement of drug laws can result in a denial of medical or income benefits.¹² While some states are legalizing marijuana for recreational purposes, recreational marijuana use is illegal in most states.¹³ Knowing about these laws, some healthcare providers may view people who use marijuana through a criminal lens. They also may see them based on stereotypes of those who have a history of marijuana use.

Although many laws governing marijuana intend to prevent its use to enhance maternal and fetal health, their implementation may indirectly limit access to care. Pregnant and postpartum women who use marijuana, for example, may be reluctant to disclose their use due to fear of punishment or a belief that healthcare providers will treat them like criminals.^{5,13}

Pregnant and postpartum women who use marijuana deserve the same quality of care as anyone else. For some, marijuana use may be a manifestation of a larger substance use

disorder (SUD). Efforts should be made to prioritize marijuana use as a health problem rather than a criminal act in states that have not decriminalized recreational use.

Information about the risks and harms of marijuana use should be presented in a factual, respectful, and non-judgmental manner to gain women's trust. Pregnant and postpartum women will be more likely to seek help if they think they will be treated with respect.

Part of addressing discrimination and prejudice is using person-first language.¹² For example, providers should refer to “a pregnant woman who uses marijuana,” not a “marijuana-using pregnant woman.”

Finally, providers should be fully educated about privacy and confidentiality statutes such as HIPAA and 42 CFR Part 2 (the federal laws and regulations protecting the privacy of people's records relating to SUDs). Misunderstanding of these statutes can lead some providers to avoid discussing marijuana use in treatment settings.



Challenge

Failure of Many Protocols and Procedures in Healthcare Settings to Accommodate Prevention Programs

Actions

- Integrate regular screening for marijuana use into routine workflows.
- Recognize that there are many prevention options such as in-office interventions, home visits, partnerships with community organizations, and referral services.
- Become educated about health insurance and other payment strategies for funding prevention efforts.

*It is important to note that unless the program in which the woman is enrolled for prenatal/post-partum care where the proposed intervention(s) will occur meets the definition of a 42 CFR program (i.e., a program that holds itself out as providing treatment for substance use disorders), it is not governed by the 42 CFR privacy regulations. Rather, HIPAA regulations would apply to the health record.

Health systems have a unique role to play in helping prevent marijuana use by pregnant and postpartum women. However, health care professionals often have much to cover in the limited time they have to spend with each individual.

Often, changes to regular office visit protocols to include prevention counseling need administrative approval. Further, many staff lack training on how to implement prevention approaches as part of their clinical practice. Systems change would require training not only for doctors, nurses, and physician assistants, but also for receptionists, office staff, technicians, and nursing assistants who have frequent contact with pregnant and postpartum women.

Communities may not have adequate referral resources for women who are having difficulties stopping their marijuana use or have other SUDs. There is also a lack of insurance coverage and other payment provisions for marijuana use-related counseling or treatment. It is important for health systems to be familiar with reimbursement strategies that enable payment for the provision of services needed to counsel or treat pregnant women at risk of using marijuana.

Laws regulating marijuana use vary widely from state to state. Many states are in the process of drafting new laws that will affect marijuana commerce and personal use. This volatile policy context complicates prevention efforts because problems, risk factors, and strategies are likely to vary by state.

In this area, there is much to learn from alcohol and tobacco use, especially laws affecting minors. With regard to tobacco and alcohol, the public is much more comfortable regulating the behavior of minors than adults. Some policy evaluations have shown that strategies designed to regulate underage use of tobacco and alcohol (namely, by limiting access and availability) can be quite successful in delaying or preventing the initiation of use, which is important because early initiation during adolescence is linked to problematic use in adulthood.^{14,15}

Similarly, policies and practices designed to reduce the harms associated with tobacco and alcohol use also have been successful. Such strategies have focused on identifying pregnant women who are using alcohol and tobacco, counseling them on the harms of use to themselves and the fetus, and helping them set and meet goals to quit using.



Challenge Wide Variance of Regulations Affecting Marijuana Use by State

Actions

- Adapt tobacco and alcohol use policy solutions that address initiation to marijuana use.
- Focus on preventing harms associated with marijuana use during the postpartum period.
- Expand Medicaid for postpartum care to ensure that women get the help they need to prevent relapse.

Reference List

1. Wiseman, S. H., Chinman, M., Ebener, P. A., Hunter, S. B., Imm, P., & Wandersman, A. (2007). *Getting to Outcomes™: 10 steps for achieving results-based accountability*. Santa Monica, CA: RAND Corporation. Retrieved from RAND Corporation website: https://www.rand.org/pubs/technical_reports/TR101z2.html
2. Chinman, M., Hunter, S. B., Ebener, P., Paddock, S. M., Stillman, L., Imm, P., & Wandersman, A. (2008). The Getting to Outcomes demonstration and evaluation: An illustration of the prevention support system. *American Journal of Community Psychology, 41*(3-4), 206–224. doi: 10.1007/s10464-008-9163-2
3. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. (2016). Promoting science-based approaches: Getting to Outcomes for teen pregnancy prevention. Retrieved from https://www.cdc.gov/teenpregnancy/practitioner-tools-resources/psba-gto-guide/pdf/tools/psba-gto_complete_508tag.pdf
4. Fixsen, D. L., Naoom, S. F., Blase, K. A., Friedman, R. M., & Wallace, F. (2005). *Implementation research: A synthesis of the literature*. (FMHI Publication No. 231). Retrieved from University of South Florida, Louis de la Parte Florida Mental Health Institute, The National Implementation Research Network website: <https://nirn.fpg.unc.edu/sites/nirn.fpg.unc.edu/files/resources/NIRN-MonographFull-01-2005.pdf>
5. Stone, R. (2015). Pregnant women and substance use: Fear, stigma, and barriers to care. *Health and Justice, 3*, 2. doi: 10.1186/s40352-015-0015-5
6. Holland, C. L., Nkumsah, M. A., Morrison, P., Tarr, J. A., Rubio, D., Rodriguez, K. L., ... Chang, J. C. (2016). “Anything above marijuana takes priority”: Obstetric providers’ attitudes and counseling strategies regarding perinatal marijuana use. *Patient education and counseling, 99*(9), 1446–1451. doi:10.1016/j.pec.2016.06.003
7. Krening, C., & Hanson, K. (2018). Marijuana—Perinatal and legal issues with use during pregnancy. *The Journal of Perinatal & Neonatal Nursing, 32*(1), 43–52. doi: 10.1097/JPN.0000000000000303
8. Miech, R. A., Johnston, L. D., O’Malley, P. M., Bachman, J. G., & Schulenberg, J. E. (2016). Monitoring the Future national survey results on drug use, 1975-2015: Volume I, secondary school students. Retrieved from Monitoring the Future website: http://www.monitoringthefuture.org/pubs/monographs/mtf-vol1_2015.pdf
9. Compton, W. M., Han, B., Jones, C. M., Blanco, C., & Hughes, A. (2016). Marijuana use and use disorders in adults in the USA, 2002-14: Analysis of annual cross-sectional surveys. *The Lancet Psychiatry, 3*(10), 954–964. doi: 10.1016/S2215-0366(16)30208-5
10. Lipari, R. N., Hedden, S. L., & Hughes, A. (2014). Substance use and mental health estimates from the 2013 National Survey on Drug Use and Health: Overview of findings. In U.S. Department of Health & Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, *The CBHSQ Report* (pp. 1–10).
11. Substance Abuse and Mental Health Services Administration and SAMHSA-HRSA Center for Integrated Health Solutions. (n.d.). Motivational interviewing. Retrieved from <https://www.integration.samhsa.gov/clinical-practice/motivational-interviewing>

12. National Academies of Sciences, Engineering, and Medicine. (2016). *Ending discrimination against people with mental and substance use disorders: The evidence for stigma change*. Washington, DC: The National Academies Press.
13. Crume, T. L., Juhl, A. L., Brooks-Russell, A., Hall, K. E., Wymore, E., & Borgelt, L. M. (2018). Cannabis use during the perinatal period in a state with legalized recreational and medical marijuana: The association between maternal characteristics, breastfeeding patterns, and neonatal outcomes. *The Journal of Pediatrics*, *197*, 90–96. doi: 10.1016/j.jpeds.2018.02.005
14. Jordan, C. J., & Andersen, S. L. (2017). Sensitive periods of substance abuse: Early risk for the transition to dependence. *Developmental Cognitive Neuroscience*, *25*, 29–44. doi: 10.1016/j.dcn.2016.10.004
15. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. (2014). *The TEDS Report: Age of substance use initiation among treatment admission aged 18 to 30*. Retrieved from https://www.samhsa.gov/data/sites/default/files/WebFiles_TEDS_SR142_AgeatInit_07-10-14/TEDS-SR142-AgeatInit-2014.pdf

Marijuana Use Prevention Resources for Implementation, Quality Improvement, and Evaluation of Programs



This chapter lists tools and resources to support marijuana use prevention among pregnant women, postpartum women, and women of child-bearing age. These resources can be used to guide practice and improve public health programming. For each resource, a website is provided. The resources are organized into the following categories:

1. Clinical Guidelines
2. Implementation Planning
3. Quality Improvement
4. Evaluation

Clinical Guidelines

The guidelines covered within this section address both marijuana and tobacco use, as a high percentage of women who use marijuana also use tobacco products (see Chapter 2). The prevention efforts that have proven successful for helping pregnant and postpartum women avoid or quit tobacco use may also be applied to marijuana use prevention efforts. This is helpful, considering that very few clinical guidelines focus exclusively on marijuana use among women of child-bearing age.

■ Marijuana Use During Pregnancy and Breastfeeding: Implications for Neonatal and Childhood Outcomes

This clinical report from the American Academy of Pediatrics provides data on the current rates of marijuana use among pregnant and breastfeeding women. The report presents information on the effects of marijuana on fetal development and later neurodevelopmental and behavioral outcomes. The report also addresses implications for education and policy. <https://pediatrics.aappublications.org/content/142/3/e20181889>

■ **Academy of Breastfeeding Medicine Clinical Protocol #21: Guidelines for Breastfeeding and Substance Use or Substance Use Disorder, Revised 2015**

A central goal of the Academy of Breastfeeding Medicine is the development of clinical protocols for managing common medical problems that may influence breastfeeding success. The purpose of Clinical Protocol #21 is to provide literature-based guidelines for addressing the needs of women with a history of past or current substance use or a substance use disorder (SUD) who are considering breastfeeding. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378642>

■ **American College of Obstetricians and Gynecologists (ACOG) Committee Opinion Number 722: Marijuana Use During Pregnancy and Lactation**

This resource focuses on marijuana use during pregnancy and lactation. It is an educational resource to aid clinicians who provide obstetric and gynecological care. <https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Marijuana-Use-During-Pregnancy-and-Lactation>

■ **ACOG Tobacco and Nicotine Cessation Toolkit**

Developed by ACOG's Wellness Work Group on Tobacco Cessation, this toolkit assists obstetrician-gynecologists and women's healthcare providers in addressing the issue of tobacco and nicotine cessation. The toolkit presents screening tools for tobacco and nicotine use (including e-cigarette use) and resources to help women stop use. <https://www.acog.org/About-ACOG/ACOG-Departments/Toolkits-for-Health-Care-Providers/Tobacco-and-Nicotine-Cessation-Toolkit>

■ **Guidelines for Identification and Management of Substance Use and Substance Use Disorders in Pregnancy**

These guidelines from the World Health Organization contain recommendations for identifying and addressing the needs of pregnant and postpartum women who use illicit substances or are diagnosed with SUDs. https://www.who.int/substance_abuse/publications/pregnancy_guidelines/en

■ **Marijuana Pregnancy & Breastfeeding Guidance: For Colorado Health Care Providers Prenatal Visits**

This evidence-based clinical resource document for healthcare providers offers language for talking to women about marijuana use during pregnancy and while breastfeeding. https://www.colorado.gov/pacific/sites/default/files/MJ_RMEP_Pregnancy-Breastfeeding-Clinical-Guidelines.pdf

■ **Pediatric Exposure Prevention: Clinical Guidance for Colorado Health Care Providers**

This resource provides information for healthcare providers to talk with parents of children and youth about marijuana use and exposure. https://www.colorado.gov/pacific/sites/default/files/MJ_RMEP_Pediatric-Parents-Clinical-Guidelines.pdf

■ **Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions**

This resource includes recommendations made by the U.S Preventive Services Task Force regarding smoking cessation and pregnant women. <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions1>

Data Resources and Survey Tools

When planning to implement a prevention program, it is important to consider how your population and community compare with others. The following data resources provide national indicators that offer a viable way to compare community indicators to national ones. The national survey tools are also good resources that can be [administered at the community level](#).

■ National Survey on Drug Use and Health (NSDUH)

This annual survey interviews people across the country to provide national and state-level estimates of tobacco, alcohol, and illicit drug use and mental health. The SAMHSA survey provides data on levels and patterns of substance use, tracks usage trends, assesses consequences, and identifies groups at high risk for substance use. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health>

■ Behavioral Risk Factor Surveillance System (BRFSS)

This CDC survey system collects state data about U.S. residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services. <https://www.cdc.gov/brfss/index.html>

■ Drug Abuse Warning Network (DAWN)

DAWN is SAMHSA's nationally representative public health surveillance system that continuously monitors drug-related visits to hospital emergency departments. DAWN monitors trends in drug misuse, identifies the emergence of new substances and drug combinations, assesses health hazards associated with drug misuse, and estimates the impact of drug misuse on the nation's health care system. <https://www.datafiles.samhsa.gov/study-series/drug-abuse-warning-network-dawn-nid13516>

■ Pregnancy Risk Assessment Monitoring System (PRAMS)

PRAMS collects state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. Data can be used to identify groups of women and infants at high risk for health problems, to monitor changes in health status, and to measure progress toward goals in improving the health of mothers and infants. <https://www.cdc.gov/prams/index.htm>

Implementation Planning

Developing and implementing prevention programs involves several steps, including the formulation of a plan that considers effective strategies and practices, as well as access points to reach women, their families, and their communities. Resources within this section provide guidance for the selection of appropriate prevention practices. Also included are materials that can be adapted from prevention programs focused on tobacco, alcohol, and other substance use prevention.

Screening Tools

■ **The Cannabis Use Disorder Identification Test—Revised (CUDIT-R)**

This is a brief, eight-item screening measure to identify hazardous cannabis use that could require intervention. https://bpac.org.nz/BPJ/2010/June/docs/addiction_CUDIT-R.pdf

■ **Patient-Reported Outcomes Measurement Information System (PROMIS)[®]**

PROMIS[®] includes more than 300 measures of physical, mental, and social health among the general population and individuals living with chronic conditions. PROMIS developed self-report measures for adults around functions, symptoms, behaviors, and feelings. <http://www.healthmeasures.net/explore-measurement-systems/promis/intro-to-promis>

Professional Education Resources

■ **Is Marijuana Safe to Use While Pregnant or Breastfeeding?**

This federal resource from the National Institute on Drug Abuse provides recommendations for healthcare providers regarding how to advise pregnant and breastfeeding women who use marijuana. <https://www.drugabuse.gov/marijuana-safe-to-use-while-pregnant-or-breastfeeding>

■ **Emory University School of Medicine, Center for Maternal Substance Abuse and Child Development**

This site offers fact sheets, resource guides, and articles on marijuana and pregnancy. <http://www.emory.edu/msacd/Individuals and Families/Information.html>

■ **Marijuana and Your Baby**

This fact sheet provides information about marijuana, pregnancy, and breastfeeding from the Colorado Department of Public Health and Environment. https://www.colorado.gov/pacific/sites/default/files/MJ_RMEP_Factsheet-Pregnancy-Breastfeeding.pdf

■ **MotherToBaby**

This website provides evidence-based information on the safety of medications and other exposures during pregnancy and while breastfeeding. The site includes fact sheets on various drugs and prescription medications and their impact on pregnancy. <https://mothertobaby.org>

■ **Weed to Know for Baby and You**

This public campaign, operated by the Spokane Regional Health District, provides facts about the harm associated with marijuana use during pregnancy, breastfeeding, and caring for a baby. <https://srhd.org/weed-to-know-baby-you>

Program Development and Community-Based Services

■ **American Academy of Pediatrics, Substance Use and Prevention: Information on Marijuana**

This website provides resources on the latest policies, education, and news regarding marijuana. <https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/Substance-Use-and-Prevention/Pages/marijuana.aspx>

■ **The Guide to Community Preventive Services (The Community Guide)**

The Community Guide is a collection of evidence-based findings of the Community Preventive Services Task Force. It is intended to help in the selection of interventions to improve health and prevent disease in states, communities, community organizations, businesses, healthcare organizations, and schools.

<https://www.thecommunityguide.org>

■ **Prevention Technology Transfer Center (PTTC) Network**

The purpose of the SAMHSA-funded PTTC Network is to improve implementation and delivery of effective substance misuse prevention interventions and provide training and technical assistance services to the substance misuse prevention field. The PTTC Network develops and disseminates tools needed to improve the quality of substance misuse prevention efforts. The network also makes technical assistance, epidemiological data, and implementation resources available. <https://pttcnetwork.org>

■ **Selecting Best-Fit Programs and Practices: Guidance for Substance Misuse Prevention Practitioners**

This resource places the selection of programs and practices within the broader context of evidence-based prevention by exploring the value of embedding program and practice selection in a strategic planning process. The guidance document provides information about how to identify and choose among appropriate programs and practices. Also included are tips for adopting, adapting, and innovating programs and practices at the local level.

https://www.samhsa.gov/sites/default/files/ebp_prevention_guidance_document_241.pdf

■ **Toking, Smoking, and Public Health: Lessons from Tobacco Control for Marijuana Regulation**

This tool is a synopsis of regulatory public health issues related to marijuana legalization that are comparable to those faced in tobacco control. The synopsis also provides an overview of options that local and state governments might consider when developing marijuana regulations. <https://publichealthlawcenter.org/sites/default/files/resources/Toking-Smoking-Public-Health-2018.pdf>

■ **Know the Risks of Marijuana**

SAMHSA's site dedicated to increasing understanding of marijuana provides public awareness messages, including ones oriented specifically to pregnancy. All of the messages can be downloaded and used at no cost. <https://www.samhsa.gov/marijuana>

Quality Improvement

Quality improvement involves systematic and continuous actions that lead to the measurable review of program outcomes and ongoing improvement activities in healthcare services. A continuous quality improvement process is directly linked to an organization's commitment to measuring the impacts of service delivery and the underlying process and systems of delivering this care.

Quality improvement can serve as a framework for improving the way prevention efforts are delivered. Most quality improvement models are based on an interactive process that continually builds on the experience and lessons learned as a prevention program is implemented.

■ **Developing and Sustaining Perinatal Quality Collaboratives : A Resource Guide for States**

Perinatal Quality Collaboratives (PQCs) are federally supported state or multi-state networks of perinatal care providers and public health professionals who work to improve health outcomes for women and newborns through continuous quality improvement. This resource guide provides information about starting statewide collaboratives, launching initiatives, using data and measurement, fostering sustainability,

and more. The guide also includes links to other useful resources for perinatal quality improvement work. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pdf/Best-Practices-for-Developing-and-Sustaining-Perinatal-Quality-Collaboratives_tagged508.pdf

■ **Plan-Do-Study-Act (PDSA)**

The PDSA cycle is part of the Institute for Healthcare Improvement Model for Improvement, a tool for accelerating quality improvement. The PDSA cycle is the scientific method used for action-oriented learning, and involves testing a change by planning it, trying it, observing the results, and acting on what is learned. <https://innovations.ahrq.gov/qualitytools/plan-do-study-act-pdsa-cycle>

Evaluation

The purpose of program evaluation is to monitor a program's impact and outcomes. Key components involve selecting program goals, establishing data outcomes to measure, determining the intended outcomes, and selecting the indicators that support those outcomes.

It is also important to determine which tools provide the best measurement of intended outcomes. Examining variations in a program's service components and delivery processes informs how outcomes are achieved, and how these impact specific populations.

Effective program evaluation can also inform policy development and change. Examples of program evaluation include:

- Monitoring the consistency with which programs and services are delivered and their adherence to established practice guidelines
- Measuring and tracking client outcomes over time
- Examining variations in outcomes for specific groups of clients

■ **CDC Evaluation Resources**

This federal website offers links to resources on understanding, developing, and using logic models to support the strategic planning and evaluation of health-related initiatives. <https://www.cdc.gov/eval/resources/index.htm>

■ **A Framework for Program Evaluation**

This framework guides public health professionals in their use of program evaluation, encouraging an approach to evaluation that is integrated with routine program operations. <https://www.cdc.gov/eval/framework/index.htm>

■ **Getting To Outcomes®: Improving Community-Based Prevention**

This federally supported toolkit is organized around a 10-step process to help communities plan, implement, and evaluate the impact of programs that seek to prevent negative behaviors among youth. <https://www.rand.org/health-care/projects/getting-to-outcomes.html>

■ **Policy Evaluation**

The CDC's National Center for Injury Prevention and Control developed this series of briefs to increase the use of policy evaluation methods in the field of injury prevention and control. <https://www.cdc.gov/injury/about/evaluation.html>

■ **RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance)**

The goal of RE-AIM is to encourage program planners, evaluators, readers of journal articles, funders, and policy makers to pay more attention to essential program elements, including external validity that can improve the sustainable adoption and implementation of effective, generalizable, and evidence-based interventions. <http://www.re-aim.org>

Appendix 1: Acknowledgments

This publication was developed with a significant contribution from Kim Dash, Ph.D., M.P.H.; Alta DeRoo, M.D.; and Tricia Wright, M.D. The guidance is based, in part, on the thoughtful input of the Planning Committee and the Expert Panel on Preventing the Use of Marijuana: Focus on Women and Pregnancy from March through September 30, 2019. A series of Planning Committee meetings was held virtually over a period of several months, and the Expert Panel meeting was convened in North Bethesda, Maryland, by the Substance Abuse and Mental Health Services Administration (SAMHSA).

Planning Committee

Joselin Bravo Bueno

Westat

Kim Dash, Ph.D., M.P.H.

Education Development Center, Inc.

Alta DeRoo, M.D.

American Society of Addiction Medicine
American College of Obstetricians and Gynecologists

Shadia Garrison, M.P.H.

Substance Abuse and Mental Health
Services Administration

Shoma Ghose, Ph.D.

Westat

Nelia Nadal, M.P.H.

Substance Abuse and Mental Health
Services Administration

Tricia Wright, M.D., M.S.

University of Hawai'i John A. Burns
School of Medicine
University of California, San Francisco
American College of Obstetricians and Gynecologists

Expert Panel

Alicia Allen, Ph.D.

University of Arizona College of Medicine

Celestina Barbosa-Leiker, Ph.D.

Washington State University

Jennifer Bishop, Sc.D.

U.S. Department of Health and Human Services
Office on Women's Health

Laura Borgelt, Pharm.D.

University of Colorado

Jessica Cotto, M.P.H.

National Institute on Drug Abuse

Shanna Cox, M.S.P.H.

Centers for Disease Control and Prevention

Elizabeth Dang, M.P.H.

Centers for Disease Control and Prevention

Alta DeRoo, M.D.

American Society of Addiction Medicine
American College of Obstetricians and Gynecologists

Lucinda (Lucy) England, M.D.

Centers for Disease Control and Prevention

Dorothy Fink, M.D.

U.S. Department of Health and Human Services
Office on Women's Health

Tista Ghosh, M.D., M.P.H.

Colorado Department of Public Health and
Environment

Karen Kuehn Howell, Ph.D.

Emory University School of Medicine

Katia Delrahim Howlett, Ph.D., M.P.P., M.B.A.

National Institute on Drug Abuse

Kathryn Icenhower, Ph.D.

SHIELDS for Families

Hendrée E. Jones, Ph.D.

UNC Horizons - University of North Carolina at Chapel Hill

Jean Y. Ko, Ph.D.

Centers for Disease Control and Prevention

Dawn Levinson, M.S.W.

Health Resources and Services Administration

Gillian Schauer, Ph.D.

School of Public Health, University of Washington

Karen Sirocco, Ph.D.

National Institute on Drug Abuse

Susan Weiss, Ph.D.

National Institute on Drug Abuse

Tricia Wright, M.D., M.S.

University of Hawai'i John A. Burns School of Medicine

University of California, San Francisco

American College of Obstetricians and Gynecologists

SAMHSA Staff

Thomas Clarke, Ph.D.

National Mental Health and Substance

Use Policy Laboratory

Shadia Garrison, M.P.H.

Center for Substance Abuse Prevention

Nelia Nadal, M.P.H.

Center for Substance Abuse Prevention

Patricia Santora, Ph.D.

Center for Substance Abuse Treatment

Photos are for illustrative purposes only.
Any person depicted in a photo is a model.

Publication No. PEP19-PL-Guide-2

SAMHSA
Substance Abuse and Mental Health
Services Administration